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ABSTRACT 
Cigarette smoking is, in developed countries, the leading cause of premature death. In tobacco 
smoke, the main addictive compound is nicotine, which in the brain binds to neuronal nicotinic 
acetylcholine receptors (neuronal nAChRs). These have been implicated in addiction, but also in 
several neurological disorders including Alzheimer’s and Parkinson’s diseases, Tourette’s 
syndrome, attention-deficit hyperactivity disorder (ADHD), schizophrenia, pain, depression, and 
autosomal-dominant noctural frontal lobe epilepsy; all of which makes nAChRs an intriguing target 
of study.   
Chronic treatment with nicotine leads to an increase in the number of nAChRs 
(upregulation) in the brain and changes their functionality. Changes in the properties of nAChRs are 
likely to occur in smokers as well, since they are exposed to nicotine for long periods of time. 
Several nAChR subtypes (e.g, α7 nAChR and β2 subunit-containing nAChRs) likely play a role in 
the formation of nicotine addiction by participating in the release of dopamine in the striatum. The 
aim of this study was to clarify at cellular level the changes in nAChR characteristics resulting from 
chronic nicotine treatment. 
SH-SY5Y cells, endogenously several nAChR-expressing, and SH-EP1-hα7 cells, 
transfected with the α7 nAChR subunit gene were treated chronically with nicotine. The localisation 
of α7 and β2 subunits was studied with confocal and electron microscopy. Functionality of nAChRs 
was studied with calcium fluorometry. Effects of long-term treatment with opioid compounds on 
nAChRs were studied by means of ligand binding.  
Confocal microscopy showed that in SH-SY5Y cells, α7 and β2 subunits formed clusters, 
unlike the case in SH-EP1-hα7 cells, where α7 nAChRs were distributed more diffusely. The 
majority of nAChR subunits localised on endoplasmic reticulum (ER). Chronic treatment with KCl 
or nicotine caused no changes in the responses evoked by KCl, but nicotine-evoked responses were 
decreased. After chronic nicotine treatment in the presence of the α7 nAChR-selective antagonist 
methyllycaconitine (MLA), the response to nicotine was higher, which suggests that α7 nAChRs 
show differing functional conformations. The isomers of methadone acted as agonists at α7 
nAChRs. Acute morphine challenge also stimulated nAChRs. Chronic treatment with methadone or 
morphine led to an increased number of nAChRs.   
In animal studies, mice received nicotine for 7 weeks. Electron microscopical analysis of the 
localisation of nAChRs showed in the striatum that α7 and β2 nAChR subunits localised 
synaptically, extrasynaptically, and intracellularly, with the majority localising extrasynaptically. 
Chronic nicotine treatment caused an increase in the number of nAChR subunits at all studied 
locations. 
  These results suggest that the α7 nAChR and β2 subunit-containing nAChRs respond to 
chronic nicotine treatment differently. This may indicate that the functional balance of various 
nAChR subtypes in control of the release of dopamine is altered as a result of chronic nicotine 
treatment. Compounds binding both to opioid and nACh receptors may be of clinical importance.  
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1. INTRODUCTION 
 
Neuronal nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated ion channels, 
composed either of α or of α and β subunits from a family of nine α (α2-α10) and three β subunits  
(β2-β4). The main role of nAChRs seems to be to modulate the release of neurotransmitters in the 
brain. Similarly to other dependence-causing substances, nicotine leads to increased release of 
dopamine (DA) in mesolimbic and nigrostriatal pathways (Di Chiara and Imperato 1988; Stolerman 
and Jarvis 1995). The nAChRs are also important in modulating the release of other 
neurotransmitters, such as noradrenaline in the hippocampus (Sacaan et al. 1995), glutamate in the 
prefrontal cortex, medial habenula, and hippocampus (McGehee and Role 1995; Vidal and 
Changeux 1993), GABA in the interpeduncular nucleus and hippocampus (Alkondon et al. 1997), 
acetylcholine in the cortex and hippocampus (Lapchak et al. 1989; Rowell and Winkler 1984), and 
5-hydroxytryptamine (5-HT) in the striatum (Reuben and Clarke 2000). Activation of nAChRs 
causes behavioural changes which may be related to these neurotransmitter release modulating 
effects. In addition to nicotine addiction, nAChRs are known to be involved in various cognitive 
functions, in the control of locomotor activity, and in pain perception (see review by Gotti et al. 
1997; Gentry and Lukas 2002). The α6β2, α6α4β2, α3β2, α4β2, and α7 nAChR subtypes are 
expressed in striatal DAergic neurons (Jones and Wonnacott 2004; Zoli et al. 2002; Salminen et al. 
2004; Wonnacott 1997; Wu et al. 2004). On glutamatergic neurons, α7 nAChRs are expressed 
(Jones and Wonnacott 2004). GABAergic neurons in the striatum express α4β2 subtypes (Klink et 
al. 2001; Marubio et al. 2003) and α7 subtype (Wooltorton et al. 2003).  
Subcellular localisation of neuronal nAChRs is largely unknown. At the simplest level, 
receptors can be classified according to localisation into three groups: intracellular, synaptic, or 
extrasynaptic; nAChRs at different localisations probably play different functional roles.  
Changes in nAChR mediated signaling have been reported in illnesses such as Alzheimer’s 
(Sugaya et al. 1990; Nordberg et al. 1988) and Parkinson’s disease (Morens et al. 1996), and in 
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schizophrenia (Freedman et al. 1997). In Alzheimer’s disease, the cortical choline acetyltransferase 
and the levels of nAChRs are decreased (Aubert et al. 1992). Parkinson’s disease is a result of loss 
of dopaminergic neurons of the substantia nigra and, as in Alzheimer’s disease activity of the 
choline acetyltransferase and the number of high-affinity [3H]nicotine-binding sites is decreased 
(Perry and Kellar 1995). In schizophrenia, there may possibly be mutations in the α7 subunit gene 
(Freedman et al. 1997).  
It is known that smoking causes changes in the function and number of nAChRs. Short-term 
exposure to nicotine causes desensitisation of nAChRs, from which they recover in a few minutes. 
Chronic treatment with nicotine is known to lead to an increased number of nAChRs (Schwartz and 
Kellar 1983; Wonnacott et al. 1990). This upregulation is reversible, and if nicotine is removed the 
number of nAChRs will return to the original level in a few days (Marks et al. 1985). Localisation 
and the functional role of new receptors appearing as a result of chronic nicotine treatment is 
unknown.   
This study examines the effects of chronic treatments with several nAChR affecting 
compounds on the localisation and functionality of α7 nAChRs and β2 subunit containing nAChRs. 
The characters of nAChRs were studied by use of steadily nAChR-expressing SH-SY5Y and SH-
EP1-hα7 cells. Changes in the localisation of subunits were also studied in mouse striatum. Effects 
of the isomers of methadone and other opioid receptor ligands on nAChRs were addressed in 
functional studies and by use of ligand binding to reveal functional connection of these two drug 
receptors mediating actions of addictive compounds. 
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2. REVIEW OF THE LITERATURE 
 
2.1.   Nicotinic acetylcholine receptors 
2.1.1 Structure of nAChRs 
Acetylcholine (ACh) receptors in the mammals CNS can be divided into muscarinic (mAChR) and 
nicotinic (nAChR) subtypes. The mAChRs mediate the diverse actions of the neurotransmitter 
acetylcholine and are expressed abundantly in the central nervous system as well as throughout 
peripheral tissues innervated by the parasympathetic nervous system (Brann et al. 1993). The 
nAChRs can be classified into muscle-type and neuronal-type receptors. Muscle-type nAChRs are 
pentameric complexes consisting of five receptor subunits and mediate ion permeation at the 
endplate of the neuromuscular junction. Neuronal-type nAChRs are also pentameric ligand gated 
ion channels. The nAChRs belong to the family of ligand-gated ion channels that includes γ-
aminobuturic acid (GABAA), glycine, and 5-HT3 receptors (Albuquerque et al. 1997; Dani and 
Heinemann 1996; Wonnacott 1997). nAChRs modulate neurotransmitter release and mediate 
neurotransmission, the actions which seem to be their main roles in the nervous system (Lukas et al. 
1999).  
To date, genes encoding 17 different subunits of the vertebrate nicotinic receptors have been 
cloned (Figure 2-1). These subunits are identified as α1-α10, β1-β4, γ, δ and ε. The nicotinic 
receptor family can be separated into three general functional classes: muscle subunits                   
(α1, β1, δ, ε, γ), standard neuronal subunits (α2-α6 and β2-β4) that form nAChRs in αβ 
combinations, and subunits (α7-α10) capable of forming homomeric nAChRs that are functionally 
inhibited by α-Bgt (Mansvelder et al. 2003; Colquhoun et al. 1997). 
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Figure 2-1. Nicotinic AChR subunits can form multiple combinations.   
 
Different receptor combinations produce nAChRs that display different pharmacological, 
physiological and biochemical profiles in relation to agonist binding, antagonist affinities, ion 
permeability, conductance kinetics, and the degree to which the receptors desensitise (Galzi and 
Changeux 1995; Luetje and Patrick 1991; Cachelin and Jagge 1991).  
 
2.1.2. Localisation of nAChRs in neurons   
Activation of neuronal nAChRs at axon endings regulates the release of neurotransmitters. The 
distance from a synapse probably determines the functional role of nAChRs. In neurons, receptors 
can be classified into groups: intracellular (in the cytoplasm, not on the plasma membrane), synaptic 
(on the plasma membrane at a synapse) or extrasynaptic (on the plasma membrane but not at a 
synapse). Somatodendritic parts of neurons also express nAChRs (Figure 2-2).  
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Figure 2-2. Localisation of nAChRs in a neuron. In neurons receptors can be localised  
intracellularly, synaptically, extrasynaptically or in somatodendritic parts. 
 
Electron microscopy (EM) studies have shown that the intensity of intracellular labelling of α7 and 
β2 nAChR subunits is high (Jones et al. 2001; Jones and Wonnacott 2004). Light microscopic 
immunostaining has revealed the presence of α7 nAChRs in both somatic and dendritic regions in 
hippocampal areas of the rat brain (Dominguez del Toro et al. 1994). Hippocampal cells in culture 
have also been shown to exhibit α7 nAChR subunit immunolabelling on somatic and dendritic 
regions of neurones (Barrantes et al. 1995; Zarei et al. 1999). It has been previously shown, by 
using patch-clamp that functional nAChRs are mostly localised perisomatically in rat hippocampal 
CA1 neurons (Khirough et al. 2003). Since extrasynaptic nAChRs are localised faraway from 
synapses the role of these nAChRs could be other than the release of dopamine. In fact, α7 nAChR 
activation and the elevation of free intracellular calcium ([Ca2+]i) regulates neuronal survival (Pugh 
and Margiotta 2000; see review by Toescu 1998), which could be one role of these nAChRs.  
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2.1.3. Clustering of nAChRs  
Studies on neuro-muscular junctions have shown that muscle-type nAChRs are expressed in groups 
or, in clusters in the postsynaptic membranes of skeletal neuro-muscular junctions and thus are not 
distributed evently (Apel et al. 1995). 
The plasma membrane is mainly composed of a fluid bilayer of phospholipids, where 
membrane proteins diffuse. The effects which receptors produce depend on the sites where they are 
localised, and Ca2+-dependent processes depend on the cellular machinery accessible from those 
sites. It is known that neurotransmitter release requires high Ca2+ concentrations (see review by 
Zucker 1993), which can be achieved in close proximity to open Ca2+ channels, in Ca2+ 
´´microdomains’’ (Llinas et al. 1992; Zucker and Fogelson 1986). Anchoring can be done by 
protein-protein interactions which link receptors to the cytoskeleton. In general, many factors may 
influence the number and subunit composition of receptors at the synapse. These include the 
availability of receptors, either in an intracellular pool or in a synaptic surface pool, the stability of 
receptors at the synapse, and the removal of receptors from the synapse either through endocytosis 
or diffusion in the plasma membrane (see review about NMDA receptors by Wenthold et al. 2003).  
Several different proteins have been identified which mediate the clustering of receptors at 
synapses (see review by Colledge and Froehner 1998). A protein called rapsyn plays an essential 
role in the clustering of muscle-type nAChRs at neuro-muscular junctions (Apel et al. 1995). 
Rapsyn is co-localised with nAChRs at the neuro-muscular junction; rapsyn and nAChRs are 
expressed together at the earliest stages of synaptogenesis and are present at 1:1 stoichiometry at 
adult synapses. Extrasynaptic nAChRs are associated with rapsyn less than the synaptic nAChRs 
(Moransard et al. 2003). Other proteins are also linked to nAChRs at the neuro-muscular junction 
(Apel et al. 1995). The scaffolding complex is formed by dystrophin, its close relative utrophin, and 
their associated proteins. Gephyrin, a 93 kD protein, mediates clustering of the glycine receptor 
(Kirsch and Betz 1995) and also induces the clustering of a GABAA receptor subtype (Essrich et al. 
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1998). In addition to nAChRs, rapsyn induces clustering of a GABAA-receptor subtype (Yang et al. 
1997). 
In the brain, clustering of neuronal type nAChRs has been suggested (Levy and Aoki 2002). 
Imaging experiments with cultured hippocampal neurons have identified α7 nAChR clusters at 
GABAergic synapses (Kawai et al. 2002). Electron microscopy (EM) studies have also suggested 
that nAChRs form clusters at axon endings (Jones et al. 2001; Levy and Aoki 2002). In the 
transfected human embryonic kidney cell line HEK-293, α3β4 nAChRs were found in 2-µm 
patches on the cell surface, whereas most  α3β2 nAChRs were more diffusely distributed (Chavez-
Noriega et al. 2000). This suggests that different nAChR subtypes may differ in their ability to form 
clusters. In rapsyn-knockout mice, their rapsyn deficiency abolished neuro-muscular but not 
neuronal nAChR clustering (Apel et al. 1997; Feng et al. 1998), showing that a protein other than 
rapsyn causes neuronal nAChRs to cluster.  
 
2.1.4. Increase in intracellular Ca2+ mediated by nAChRs  
Binding of two agonist molecules to the pentamer opens the nAChR channel, which non-selectively 
conducts cations. Most of the nAChR-mediated current is carried by Na+ and K+, but Ca2+ can also 
make a significant contribution (Figure 2-3) (Castro and Albuquerque 1995). The conductance of 
various ions depends on the subunit composition of the receptor (Lindström et al. 1995).  
 
Figure 2-3. An ion channel is formed in the middle of a nAChR. Binding of acetylcholine to 
nAChR causes the channel to open. Na+ and Ca2+ flux into the cell and K+ fluxes outside the cell.   
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Various mechanisms are involved in the increase of free intracellular Ca2+ ([Ca2+]i);  
(1) Ca2+ may enter a cell through Ca2+ permeable receptors such as nAChRs and N-methyl-D-
aspartate (NMDA) receptors. α3 subunit containing nAChRs and α7 nAChR have been 
shown to raise [Ca2+]i levels indirectly, by producing sufficient current to depolarise the 
membrane and subsequently activate influx routes of Ca2+ (Vijayaraghavan et al. 1992; 
Rathouz et al. 1995). Raising of the levels of Ca2+ within the cytosol allows intracellular 
Ca2+ to be released into the cytosol of the cell (Dajas-Bailador et al. 2002a).  
 
(2) Voltage-operated Ca2+ channels (VOCCs) mediate most of the nicotine evoked-response 
(Dajas-Bailador et al. 2002a). VOCCs are classified according to activation threshold, 
kinetics, conductivity and pharmacology to L-, T-, N-, P-, Q-, and R-type channels. N-, P-, 
Q-, and R-types can be blocked by Cd2+ (Lopez et al. 1993). 
 
(3) Ca2+ can also be released into the cytoplasm from internal stores, from channels located on  
the endoplasmic reticulum (ER) (Taylor and Broad 1998). The ER maintains a large [Ca2+]i 
gradient (Berridge et al. 1998). The presence of inositol 1,4,5-trisphosphate (IP3) and 
ryanodine receptors on the surface of the ER allows for the release of accumulated stored 
Ca2+ into the cytosol of the cell, if Ca2+ levels are raised within the cytosol (Dajas-Bailador 
et al. 2002a).       
 
Ca2+ acts as an internal signal and can be considered a universal ionic messenger important in 
cellular signal transduction and as playing a role in a variety of neuronal processes. Neuronal 
nAChRs, in particular, α7 nAChR have a high relative permeability to Ca2+ compared to that of the 
majority of other ligand-gated ion channels. For example, nAChRs composed of α7 subunits exhibit 
almost a 10 : 1, Ca2+ : Na+ permeability ratio, which exceeds that of the NMDA receptor and          
the ~4 : 1 ratio of most other nAChRs (Hogg et al. 2003; Lindström 1996). The opening probability 
  
16
 
of neuronal nAChR channels is potently modulated by external Ca2+ (Fieber and Adams 1991; 
Sands and Barish 1992; Amador and Dani 1995; Dani and Mayer 1995). It is well established that 
nAChR of different subunit composition exhibit very different pharmacological and functional 
properties. Influx of Ca2+ through the activated receptor serves to measure nAChR function. The 
resting concentration of free intracellular calcium ([Ca2+]i) within a cell is usually in the range of 50 
to 100 nM, which is about ten thousand times lower than that of extracellular (Taylor and Broad 
1998). Ca2+ homeostasis in neurons is based on multiple mechanisms (Figure 2-4).  
 
Figure 2-4. A schematic representation of Ca2+ homeostasis in a cell. a) Ca2+ and Na+ influx along 
with K+ efflux in receptor-gated ion channels such as nACh and glutamate receptors; b) Ca2+ efflux 
via an ATP-requiring ionic pump; c) Ca2+ influx via voltage-operated Ca2+ channels; d) Ca2+ efflux 
via Na+/Ca2+ exchanger; e) additional ionic channels contributing to membrane repolarisation and 
ionic homeostasis; f) Ca2+ flux through the nuclear membrane with potential effects on nucleic acid 
transcription; g) Ca2+ sequestration by mitochondria; h) Ca2+ sequestration (and release) by 
endoplasmic reticulum; i) intracellular Ca2+ buffering by Ca2+-binding proteins. ATP, Adenosine 
triphosphate; ADP, adenosine diphosphate. Adopted from Sattler and Tymianski 2000 with 
permission of the publisher.  
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2.1.5. Expression of nAChRs in various tissues 
In situ hybridisation and immunohistochemistry studies have shown that various nicotinic subunits 
have different, but overlapping distributions (Table 2-1) (see review by Gotti et al. 1997). The α4 
and β2 subunit-containing nAChRs are the most common and are widely expressed throughout the 
mammalian brain including the midbrain DA areas and the striatum (Wada et al. 1989; Colquhoun 
et al. 1997). After α4 and β2 subunit containing nAChRs, α7 subunit containing nAChRs are the 
next most abundant (Seguela et al. 1993). The α7 mRNA is widely distributed, with high levels in 
the forebrain, amygdala, hippocampal structures, and olfactory regions (Seguela et al. 1993). The 
other subunits have a more restricted distribution: For example, α6 and β3 gene transcripts are 
limited to areas containing DAergic and noradrenergic cell bodies (Le Novere et al. 1996; Goldner 
et al. 1997). The mRNA for α2 and the α3 mRNA are much less widely distributed, with α3 
mRNA being mainly restricted to thalamic areas, a few discrete areas of the hypothalamus, motor 
cortex, and locus coeruleus; α2 mRNA is mainly restricted to the interpeduncular nucleus (Wada et 
al. 1989). The mRNA for α5 also display restricted distribution (Le Novere et al. 1996). The 
distribution of β4 mRNA is less widespread than β2 but is still found in significant quantities in the 
hippocampus, medial habenula of the thalamus, interperduncular nucleus, olfactory regions, and 
forebrain (Dineley-Miller and Patrick 1992).  
Due to the overlapping patterns of mRNA expression, it is possible that individual neurons 
are able to express more than one type of nAChR. It must also be borne in mind that because 
mRNA is expressed in the cell body area of the neuron, its expression pattern in the brain can differ 
from that of the subunit protein expressed on the nerve terminals and/or dendrites. The nAChR 
subunits are also expressed in non-neuronal cells, including lymphocytes, skin, epithelial cells (see 
review by Gotti et al. 1997) and microglia (Shytle et al. 2004). Cholinergic innervation throughout 
the brain ensures that nAChRs are important modulators of neuronal excitability.  
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Table 2-1. Subunit compositions of well-established nAChRs and their expression areas in human 
and chick.  
 
Subunit             Expression 
(α1)2β1γδ Fetal skeletal muscle 
(α1)2β1εδ Adult skeletal muscle 
 α3β4 Autonomic ganglia 
 α3α5β4 Autonomic ganglia 
 α3α5β2β4 Autonomic ganglia  
(α4)2(β2)3 CNS 
 α4α5β2 CNS 
 α7 Autonomic ganglia, CNS 
 α7α8 Chick retina, chick CNS 
 α8 Chick retina 
 α9 Cochlea, pituitary 
 α10 Cochlea, lymphosytes 
   
Modified from Lukas et al. 1999 with permission of the publisher. 
 
2.1.6. Distribution of nAChRs in the mesotelencephalic dopaminergic system 
DAergic neurons can be divided into three major classes depending on the length of the 
dopaminergic tract: ultrashort, intermediate-length, or long-length systems (Cooper et al. 2003). 
The long projections consist of three separate tracts: nigrostriatal, mesolimbic, and mesocortical 
projections (Skagerberg et al. 1984) (Figure 2-5 and 2-6). 
Cell bodies of the neurons forming the major ascending DAergic pathways are located in the 
brainstem, in the substantia nigra pars compacta (SNc) (A9), or ventral tegmental area (VTA) (A10) 
(Ungerstedt 1971). The A9 neurons project mainly to the dorsal striatum forming the nigrostiatal 
DA system (Fuxe et al. 1985). A minor component of the nigrostriatal system projects from the A8 
area (right retrorubral field) to the ventral putamen (Björklund and Lindvall 1984). The mesolimbic 
DAergic pathway is formed by neurons that project from the A10 area to the nucleus accumbens 
(NAc), olfactory tubercle (OT), and other limbic regions such as the amygdala, hippocampus, and 
septum. In addition, the A10 area sends axons to the cortical areas, and this system is known as the 
mesocortical DAergic pathway (Björklund and Lindvall 1984).  
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Figure 2-5. Schematic representation of the major dopaminergic systems. The nigrostriatal system 
originates in the A9 cell group and extends to the dorsal striatum, which includes the caudate 
nucleus and putamen (CPU). The mesolimbic system originates primarily in the A10 cell group and 
extends to the ventral striatum, which includes the nucleus accumbens (NAc) and the olfactory 
tubercle (OT). The mesocortical system also originates primarily in the A10 cell group and affects 
various regions of the cerebral cortex. Modified from Di Chiara 1990 with permission of the 
publisher. 
 
                                                 
The striatum consists of dorsal and ventral parts. The dorsal striatum receives DA innervation 
primarily from the SNc and to a lesser degree from the VTA. The ventral striatum is the ventral 
conjunction of the caudate and putamen that merges into and includes the NAc and striatal portions 
of the OT. GABAergic neurons project from the VTA to both the NAc (Van Bockstaele et al. 1995) 
and to prefrontal cortex (Carr and Sesack 2000) (Figure 2-6). The dorsal striatum receives 
glutamatergic inputs from sensorimotor-related cortical areas (Haber et al. 2000). 
 
 
 
 
 
  
20
 
 
Figure 2-6. Simplified image of projections in the mesotelencephalic dopaminergic system. 
DAergic and GABAergic neurons project from VTA and SNc to striatum. 
 
 
The excitatory inputs to the VTA DAergic neurons are glutamatergic projections from the 
prefrontal cortex (Taber et al. 1995; Carr and Sesack 2000) and from the pontine tegmentum 
(Charara et al. 1996). The inhibitory inputs to VTA neurons are GABAergic, including local 
interneurons as well as projections from the NAc and the ventral pallidum (Kalivas 1993). The 
physiological nAChR-activating ligand acetylcholine is released from cholinergic interneurons, 
which form about 2% of the striatal neurons (Zhou et al. 2002). Cholinergic cell bodies are localised 
in an axis running from the cranial nuclei of the brain stem to the medullary tegmentum and 
pontomesencephalic tegmentum, continuing through the diencephalon to the telencephalon (Woolf 
1991; Hallanger et al. 1987; Oakman et al. 1995). Acetylcholine activates both the GABAergic and 
DAergic neurons in the SNc and VTA (Blaha et al. 1996). 
On striatal DAergic neurons α6β2, α6α4β2, α3β2, α4β2, and α7 nAChR subtypes are 
expressed (Jones and Wonnacott 2004; Zoli et al. 2002; Salminen et al. 2004; Wonnacott 1997; Wu 
et al. 2004). In DAergic neurons, α6 is the predominant form of nAChR subunit mRNA that 
extensively co-localises with nAChR β3 subunit mRNA (Le Novere et al. 1996). 
Immunoprecipitation studies in rats and mutant mice have suggested that α4β2 and α6β3β2 are the 
primary nAChR subtypes in rodent DA terminals, with a possible contribution of α6(α4)β2β3, and 
α4β5β2 subunit combinations (Zoli et al. 2002; Champtiaux et al. 2003; Salminen et al. 2004). The 
α7 nAChR subunits are not highly expressed in the striatum (Seguela et al. 1993; Clarke and Pert 
1985; Dominguez del Toro et al. 1994), and may be preferentially involved in mediation of the 
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presynaptic effects of nicotine on glutamate release (Girod et al. 2000; McGehee and Role 1995). 
The cholinergic regulation of DA release in the striatum seems to be controlled by sophisticated 
functional connections between different nAChR subtypes which are localised on excitatory and 
inhibitory neurons (Figure 2-7). 
 
 
 
Figure 2-7. Expression of nAChR subunits in mesotelencephalic dopaminergic system. On striatal 
DAergic neurons α6β2, α6α4β2, α3β2, α4β2 and α7 nAChR subtypes are expressed. α7 and α3 
subunits are not expressed in axon endings (Salminen et al. 2004). Glutamatergic neurons express 
α7 nAChRs. In addition to DAergic neurons also GABAergic neurons in the striatum express α4β2 
subtypes. DA, dopaminergic; GABA, GABAergic; Glu, Glutamatergic. Adapted from Champtiaux 
et al. 2003 with permission of the publisher. 
 
 
Nicotine can affect the release of DA through three different routes; 
(1) Nicotine can activate nAChRs on DAergic neurons. β2 Subunit containing nAChRs play a 
major role in the nicotine-evoked release of DA through DAergic neurons (Picciotto et al. 
1998; Grady et al. 2001).  
(2) Nicotine can desensitise extrasynaptic α4β2 nAChRs on GABAergic neurons in the VTA 
which then interact with DAergic cell bodies, resulting in disinhibition and an increase in DA 
cell firing (Mansvelder et al. 2002; Wooltorton et al. 2003).  
(3) Nicotine can activate α7 nAChRs located on glutamatergic nerve terminals in the VTA that do 
not appear to desensitise as profoundly as do nAChRs on GABAergic terminals, and elevate 
glutamate release (Mansvelder et al. 2002; Wooltorton et al. 2003).  
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Damage to the VTA reduces the binding of [3H]nicotine to somatodendritic parts of mesolimbic 
DAergic neurons and nerve endings (Clarke and Pert 1985). This indicates that nAChRs are 
expressed in the VTA. In microdialysis studies the concentration of extracellular DA is elevated in 
mesolimbic areas as a result of systemically administered nicotine. This rise in the level of DA can 
be prevented by mecamylamine, showing that nAChRs participate in the release of DA (Benwell et 
al. 1992). Nicotine-evoked increase in the level of DA in the NAc is thought to be predominantly 
mediated by nAChRs in the VTA, since when mecamylamine is infused into the VTA, DA release 
is abolished, but not when mecamylamine is infused into the NAc (Nisell et al. 1994). 
 
2.1.7. nAChR subunit knockout mice 
Given the wide diversity of receptors sensitive to nicotine, it is of interest to determine which 
subtypes of the nAChR mediate various effects of nicotine. Lack of specific ligands binding to 
differing nAChR subtypes can be overcome by producing knockouts which do not express some of 
nAChR subunits (see review by Marubio and Changeux 2000). Several different single nAChR 
subunit lacking knockout mice have been produced (Table 2-2). Knockouts can be produced by 
injecting engineered embryonic stem cells into mouse blastocysts, after which they are re-implanted 
into a host mother's uterus, and lack the deleted gene permanently (Capecchi 1989).  
Studies have shown that the α7 nAChRs are not involved in the rewarding effects of 
nicotine (Grottick et al. 2000). The α7 subunit is expressed in the early phases of fetal development 
(Broide 1995), but its’ absence does not inhibit normal brain development (Orr-Urtreger et al. 
1997). Radioligand binding studies, done by using knockout mice, have shown the role of subunits 
in binding of nAChRs affecting compounds. [125I]-α-Bgt does not bind to brain extracts of α7 
knockouts (Orr-Urtreger et al. 1997); [3H]Nicotine binds with high affinity to brain extracts of α7 
knockouts, but not to the extract of β2 knockouts (Booker 1999). The binding of [3H]nicotine in α4 
knockouts fails to disappear completely (Marubio et al. 1999). 
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Behavioural studies have shown that the β2 subunit containing nAChRs are involved in the 
reinforcing properties of nicotine (Picciotti et al. 1998). Studies with α3 knockouts have shown that 
the α3 subunit participates in the release of dopamine in the striatum (Booker 1999) and that the α3 
subunit mediates fast synaptic transmission (Xu et al. 1999). The β4 subunit is critical for nicotine 
withdrawal symptoms in mice, whereas the β2 subunit is not (Salas et al. 2004).  
Knockout animals make it possible to study in vivo the effects of nAChR subunits on 
cellular and morphological phenotype and behaviour, which cannot be studied in vitro. 
Table 2-2.  Functional abnormalites in mice following nAChR gene deletion.  
nAChR 
subunit 
Cellular/morphological 
phenotype 
Behavioural 
phenotype 
Survival References 
α3 Autonomic nervous 
system defects; 
mydriasis  
 1-8 weeks 
postnatal 
Xu et al. 1999 
α4 Loss of high-affinity 
nicotine binding 
Reduced nicotine-
elicited 
antinociception 
Adult Marubio and 
Changeux 
et al. 2000 
α7 Lack of rapidly 
desensitising nicotine 
currents in hippocampal 
neurons 
Normal baseline 
responses 
Adult Orr-Urtreger  
et al. 1997 
α9 Abnormal efferent 
innervation of hair cells 
in the cochlea 
Suppression of 
cochlear responses
Adult Vetter et al. 
1999 
β2 Altered agonist 
sensitivity; loss of 
presynaptic receptor 
activity in GABAergic 
terminals, high-affinity 
nicotine binding, 
nicotine-induced DA 
release. Accelerated 
ageing. 
Enhanced passive 
avoidance 
responses; loss of 
nicotine self-
administration 
activity, altered 
learning in aged 
animals, reduced 
nicotine-elicited 
antinociception 
Adult Picciotto  
et al. 1995; 
1998,  
Zoli et al. 
1998 
β4 Reduced nicotine- 
elicited current 
 Adult Xu et al. 1999 
β2/β4 Autonomic nervous 
system defects; enlarged 
bladder and dilated 
ocular pupils 
 Increased 
mortality 
Xu et al. 1999 
ε Abnormal development 
of motor endplates 
 8-14 weeks 
postnatal 
Witzemann et 
al. 1996; 
Missias et al. 
1997 
Modified from Marubio and Changeux 2000 with permission of the publisher. 
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2.1.8. nAChRs and behaviour 
The craving for the rewarding properties of an addictive drug and the avoidance of the unpleasant 
symptoms of drug withdrawal are both likely to contribute to the maintenance of drug-taking 
behaviour (Balfour 1991). The rapid delivery of nicotine from smoke allows smokers to adjust their 
smoking patterns (Benowitz et al. 1991). Nicotine is considered to act both as a positive and as a 
negative reinforcer (Stolerman and Jarvis 1995): The concept of positive reinforcement is connected 
with the pleasurable experiences associated with smoking. If a person smokes to escape the 
psychological discomfort related to withdrawal and thus relieve anxiety and depression, nicotine 
acts as a negative reinforcer (Di Chiara 1992). 
Nicotine has also positive effects. Studies on animals have indicated that nicotinic agonists 
can have positive and potentially long-lasting effects on cognition. Memory in animals improves in 
tests of cognitive behaviour (see review by Levin 1992; Levin and Chen 2004). In humans nicotine 
is able to increase arousal, visual attention, and perception (Newhouse et al. 1997; Jones et al. 
1992). Short-term memory may be improved by facilitated storage of received inputs (see review by 
Levin 1992). The effect of nicotinic drugs on human cognitive functions has yet to be completely 
elucidated. 
It is commonly believed that nicotine reduces anxiety and clinical data exists to support this 
(Pomerleau et al. 1986). Studies in drug-naive animals have demonstrated anxiolytic activity for 
nicotinic agents (Scheufele et al. 2000). Rodents treated acutely with nicotine or a nicotinic agonist, 
ABT-418, have displayed anxiolysis in the elevated plus maze test in comparison to that for saline 
treated-animals (Decker et al. 1994). 
Nicotine acts as an antinociceptive agent in animals (see review by Decker et al. 2004; 
Carstens et al. 2001; Damaj et al. 2000; Mattila et al. 1968). The nAChRs containing the α4 subunit 
in association with the β2 subunit are suggested to be crucial for nicotine-elicited antinociception 
(Marubio et al. 1999). The potent nicotinic agonist epibatidine has been found to possess analgesic 
activity with a potency 200-fold more effective than that of morphine (Badio and Daly 1994). 
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2.1.9. Connections between opioid and nACh receptors and their ligands 
Nicotine administration causes the release of endogenous opioids in rat NAc and mouse striatum 
(Davenport et al. 1990; Dhatt et al. 1995; Houdi et al. 1991; Pierzchala et al. 1987; Pomerleau et al. 
1984). The opioid system consists of three G-protein-coupled receptors; μ, δ, and κ, which are 
stimulated by endogenous opioid peptides (Kieffer 1995). Endogenous opioid plasma levels are 
increased following smoking, paralleling increases in plasma nicotine levels (Pomerleau et al. 
1983).   
The analgesic effects of nicotine have been known for decades (Mattila et al. 1968).  
Epibatidine, an agonist at α4β2 nAChRs, has been shown to be 200-fold more potent than morphine 
in experimental pain models (Badio and Daly 1994). Epibatidine’s analgesic properties are 
presumably mediated by nAChRs, since it can be prevented by the nAChR antagonist 
mecamylamine but not by the opioid receptor antagonist naloxone (Badio and Daly 1994; Damaj et 
al. 1994). However, naloxone has been shown to block the antinociceptive effects of nicotine in 
some mouse models (Tripathi et al. 1982; Zarrindast et al. 1997). The specific involvement of μ-
opioid receptors in nicotine-opioid interactions has been shown by the attenuation of nicotine 
antinociception in μ-opioid receptor knockout mice (Berrendero et al. 2002). Different endogenous 
opioid peptides derived from three protein precursors (proopioidmelanocortin, proenkephalin, 
prodynorphin) show high affinity for the μ-opioid receptor. It has been suggested that nicotine may 
elevate the levels of endogenous opioid peptides derived from preproenkephalin, which would 
participate in the antinociceptive effects induced by nicotine, presumably by stimulating μ-opioid 
receptors (Berrendero et al. 2005). Studies done on preproenkephalin knockout mice have shown 
that endogenous opioid peptides derived from preproenkephalin are involved in the antinociceptive 
and rewarding properties of nicotine and participate in the expression of physical nicotine 
dependence (Berrendero et al. 2005). The functional connection between nAChRs and opioid-
receptors in producing antinociceptive effects remains to be clarified. 
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Enkephalinergic interneurons as well as enkephalinergic inputs from the NAc are present in 
the VTA (Garzon and Pickel 2000). It has also been suggested that nicotine may induce indirectly 
through glutamate transmission a release of endogenous opioid peptides derived from 
preproenkephalin (Isola et al. 2000). This release would inhibit GABAergic neurotransmission 
through activation of presynaptic μ-opioid receptor (Berrendero et al. 2002) localised on the 
terminals of GABAergic neurons (Bergevin et al. 2002), thus contributing to a net increase in DA 
release.  
Clinical studies examining the efficacy of opioid receptor antagonists in blocking cigarette 
craving have produced mixed results ranging from ineffectiveness for smoking cessation to mild 
reductions in the desire to smoke (Covey et al. 1999; King and Meyer 2000; Wong et al. 1999). The 
opioid receptor antagonist naloxone leads to increased somatic withdrawal signs in nicotine-
dependent rats without affecting accumbal dopamine release (Carboni et al. 2000) and in humans 
(Krishnan-Sarin et al. 1999). However, both naloxone (Tome et al. 2001) and naltrexone (Almeida 
et al. 2000) block nAChRs, suggesting that opioid receptor antagonists may precipitate nicotine 
withdrawal, at least in part by blocking nAChRs.  
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2.2.    Effects of drug treatments on nAChRs 
2.2.1. Compounds binding to nAChRs 
The nAChRs have several binding sites for ligands (Figure 2-8). Ligands can be subdivided into 
five groups; 
(I) Acetylcholine and other agonists like nicotine and epibatidine, transiently activate the 
receptor and act as depolarising agents.  
(II) Allosteric modulator compounds like physostigmine and codeine facilitate receptor  
activation by agonists. 
(III) Antagonists such as dihydro-β-erythroidine (DHβE) and methyllycaconitine (MLA) 
compete with agonists for receptor binding but do not activate them.  
(IV) Noncompetitive antagonists such as ibogaine bind to a site other than acetylcholine.  
(V) Channel blockers such as mecamylamine block ion fluxes by binding to the channel.  
 
Figure 2-8. nAChRs have several different binding sites for ligands. A representation of the 
allosteric sites on nAChR (Modified from Dani 2001 with permission of the publisher). 
 
 
Agonists 
Epibatidine is an alkaloid found in the skin of the frog Epipedobates tricolor (Daly et al. 1980). It 
binds to and activates subtypes containing the α2, α3, and α4 subunits with picomolar affinity 
(Sullivan et al. 1994). At higher nanomolar concentration, it also binds to α7 subtype (Gerzanich et 
al. 1995). Isomers of epibatidine are potent ligands for chicken nAChR subtypes: α3β2, α3β4, 
α4β2, α7, and α8, and human: α3β2, α3β4, and α7 nAChRs (Gerzanich et al. 1995). Epibatidine 
has been 200-fold more effective than morphine in antinociception (Badio and Daly 1994). Due to 
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its beneficial pharmacological properties, epibatidine has served as a leading compound in attempts 
to find clinically useful compounds (Holladay et al. 1997).  
Allosteric modulators 
In addition to receptor activation through the agonist binding site, an allosteric modulation of 
nAChR has also been described for some ligands. In vitro studies have shown that the acetylcholine 
esterase inhibitors physostigmine and galanthamine can potentiate the effects of nicotine (Okonjo et 
al. 1991; Pereira et al. 1993a; 1993b; Pereira et al. 1994). Allosteric modulators do not elicit whole 
cell currents (Maelicke et al. 1995) and they desensitise nAChRs more weakly than do classical 
agonists (Pereira et al. 1993b; 1994; Storch et al. 1995). Classical nAChR antagonists do not inhibit 
the effects of modulator compounds, which shows that the binding site of modulator compounds is 
different from that of ACh (Okonjo et al. 1991). The effect of modulator compounds can be blocked 
by a monoclonal antibody, FK1, which binds to α subunits. This shows that the effects are mediated 
by binding sites that are located on α subunits distinct from those for acetylcholine (Schröder et al. 
1994). The effects that modulator compounds have on nAChRs may depend on the concentration of 
the compound. At low concentrations these compounds, can have allosteric effects, while at higher 
concentrations they can act as antagonists (Maelicke et al. 1995). The physiological role of 
modulator compounds is unclear. It has been suggested that endorphins, enkephalins, and 5-HT can 
function as modulator compounds of nAChR (Maelicke et al. 1995; Schrattenholz et al. 1996). 
Antagonists 
Methyllycaconitine (MLA) is a toxic alkaloid which is naturally expressed in Delphinium and 
Consolida species (Nambi-Aiyar et al. 1979). It acts as a reversible, competitive antagonist and is 
selective for the α7 subtype at low nanomolar concentrations (Davies et al. 1999; Ward et al. 1990). 
Picomolar concentrations are sufficient to inhibit homomeric α7 nAChRs in Xenopus oocytes 
(Palma et al. 1996). When the concentration is raised, MLA also binds to other subtypes, such as to 
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α3β2 (>100 nM) and to α4β2 receptors (μM concentrations) (Davies et al. 1999). The small size 
and hydrophobicity of MLA makes it possible to study the amount of receptors inside the cells in 
situ.  
α-Bungarotoxin (α-Bgt), a snake venom-derived α-neurotoxin isolated from Bungarus 
multicinctus, is the classic competitive antagonist of nAChRs (Chiappinelli 1995). It is selective for 
α7, α8, and α9 subtypes. The α7 nAChRs are the predominant form of α-Bgt binding sites in the 
brain. Because of the large size of the molecule (8 kDa), it cannot cross cell membranes (Loring and 
Zigmond 1988; Davies et al. 1999).  
Dihydro-β-erythroidine (DHβE) is a derivative of erythroidine isolated from trees and 
shrubs of the genus Erythrina. It is a competitive antagonist of muscle and neuronal nAChRs 
(Williams et al. 1984; Sheridan et al. 1986) and acts competitively on several neuronal nAChR 
subunit combinations (Harvey and Luetje 1996) being very effective in blocking cation flow 
through α3β2 nAChRs (Peng et al. 1994).  
 
Channel blockers 
Mecamylamine blocks the ion channel of nAChRs (Martin et al. 1990). No large differences in  
sensitivities betweeen α4β2 and α7 nAChRs to mecamylamine have been shown (Chavez-Noriega 
et al. 1997). NMDA receptors also seem to be affected by mecamylamine (Snell and Johnson 1989). 
 
2.2.2. Effect of acute nicotine treatment on neuronal nAChRs 
 
Binding of agonist to nAChR opens the ion channel, but following prolonged or repetitive 
stimulation, a decrease or loss in biological response occurs (Dani 2001; Karlin 2002). In 
neurophysiology a form of tolerance or adaptation is known as desensitisation, which is a general 
characteristic of ligand-gated channels. nAChR desensitisation may play an important role in many 
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biological processes including the regulation of muscarinic receptors, synaptic plasticity, learning, 
and memory (Kelley 2002; Nishizaki et al. 2000). 
In vitro studies have suggested that prolonged nicotine exposure induces persisting loss 
(lasting minutes to hours) in nAChR function beyond that associated with nAChR desensitisation, 
which is a transient (reversible within seconds-minutes) loss of nAChR function during a brief 
(seconds to minutes) exposure to nicotinic agonist (Lester and Dani 1994; Reitstetter et al. 1999). 
Simplified states in which nAChRs can exist are: resting state (R), open-channel state (O), fast-
onset desensitised state (I), and slow-onset desensitised state (D) (Karlin 2002). 
The nAChR subtypes desensitise and recover from a desensitised state in differing ways 
depending on agonist concentrations (Peng et al. 1994). Whether a nicotinic agonist causes or 
inhibits responses depends not only on the subunit composition of the subtype, but also on the 
length of the exposure and the concentration of the agonist (Marks et al. 1999). The β subunit plays 
a dominant role in desensitisation kinetics for heteromeric nAChRs. The α7 nAChRs have the 
fastest desensitisation kinetics and also recover rapidly from the desensitised state (Fenster et al. 
1997; Broide and Leslie 1999). Nicotine plasma levels in smokers are around 200 nM (Gourlay and 
Benowitz 1997). In smokers, an average nicotine concentration first inactivates α4β2 subtypes and 
the α3 subunit-containing nAChRs; other subtypes are affected at higher concentrations of nicotine 
(Peng et al. 1997). At low concentrations of nicotine, nAChRs containing β2 subunits reach near-
maximal desensitisation more rapidly than do β4-containing receptors (Nelson and Lindström 
1999). At a cholinergic synapse, approximately 1 mM ACh is rapidly released into the cleft, causing 
an immediate activation of nicotinic receptors, followed by desensitisation. In a few milliseconds, 
ACh is hydrolysed by acetylcholinesterase or diffuses away, or both processes occur. The 
breakdown of ACh leads to the formation of choline, which could reach locally high concentrations. 
Choline acts as an agonist at the α7 nAChR (Damaj et al. 2000) and high concentrations of choline 
may desensitise α7 nAChRs (Alkondon et al. 1997; Papke et al. 1996). Thus the released ACh can 
cause activation-desensitisation cycles of differing subtypes in a temporally differing fashion.  
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In the VTA, desensitisation plays a role in the regulation of the release of DA. The α4β2 
nAChRs have been shown to localise on GABAergic neurons where nicotine can desensitise α4β2 
nAChRs. It has been suggested that desensitisation results in lack of inhibition from GABAergic 
cells, which interact with DAergic cell bodies, resulting in an increase in the release of DA 
(Wooltorton et al. 2003). 
 
2.2.3. Effect of chronic nicotine treatment on neuronal nAChRs 
During chronic nicotine treatment, the number of nAChRs is increased (upregulated). Upregulation 
of nAChRs has been demonstrated in vitro in several cell lines (Peng et al. 1994; Gopalakrishnan et 
al. 1997; Wang et al. 1998) and animals (Schwart and Kellar 1983; Marks et al. 1985; Pietilä et al. 
1998: Nuutinen et al. 2005) and also has been shown in the post mortem brain of smokers (Marks et 
al. 1985; Breese et al. 1997). Upregulation of nAChRs is paradoxical (see review by Wonnacott 
1990). G-protein-coupled receptors are downregulated by chronic agonist treatment (Creese and 
Sibley 1981).  
Receptor selective antagonists such as methyllycaconitine (MLA) also cause upregulation of 
number of α-Bgt binding sites. This indicates that receptor occupancy, either by an activator or an 
antagonist ligand, is sufficient to trigger an increase in receptor levels (Gopalakrishnan et al. 1997; 
Molinari et al. 1998). It has been shown that upregulation of the number of α7 nAChRs in 
sympathetic neurones is evoked also by chronic KCl depolarisation (De Koninck and Cooper 1995). 
This shows that the binding of ligand to nAChR is not required for upregulation and may result 
from Ca2+-influx through L-type Ca2+ channels and from the activation of a Ca2+-calmodulin-
dependent kinase (CaM-kinase II) pathway (De Koninck and Cooper 1995).  
The effect of chronic nicotine exposure among various nAChR subtypes differs (Olale et al. 
1997). The final outcome of chronic ligand exposure depends on various factors such as nAChR 
subtype, ligand concentration, and exposure time. Upregulation is reversible, with receptor number 
returning to control levels in 4 to 8 days after withdrawal of chronic nicotine (Schwart and Kellar 
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1983; Marks et al. 1985). In vivo, the α4β2 subtype is affected most (Flores et al. 1997; Peng et al. 
1994). The α3 subunit-containing and α7 nAChR subtypes require greater concentrations of 
nicotine than does the α4β2 to be upregulated (Peng et al. 1997). Plasma levels of nicotine in 
smokers will not reach the levels of nicotine required to upregulate these subtypes (Henningfield et 
al. 1993). The α3 subunit-containing nAChRs and α7 nAChR respond to chronic nicotine treatment 
differentially, since chronic nicotine treatment induces a 500 to 600% increase in the number of α3 
subunit-containing nAChRs but only a 30% increase in α7 nAChRs (Peng et al. 1997). Most of the 
nicotine-induced increase in α3 subunit-containing nAChRs is intracellular (Peng et al. 1997).  
In the brain of rodents, no substantial upregulation of mRNAs encoding the major nAChR 
subunits has been detected after chronic nicotine treatment even though the number of nAChRs is 
increased (Pauly et al. 1996; Mugnaini et al. 2002). This implies that upregulation of nAChR 
subunits is not a result of increased protein synthesis but is mediated via a post-transcriptional 
mechanism. Upregulation of the α4β2 subtype can be induced by exposure to membrane-
impermeable ligands. This has led to the suggestion that upregulation is mediated primarily by 
interaction with cell-surface receptors (Whiteaker et al. 1998), possibly by changes in subunit 
turnover (Peng et al. 1994). The surface trafficking of muscle-type nAChRs has been shown 
(Marchand et al. 2002). Neuronal nAChRs may traffic in a manner similar to that of their muscle 
counterpart, but because there are multiple heteromeric and homomeric subtypes of neuronal 
nAChR expressed, the mechanisms for regulation and trafficking between subtypes may vary. The 
precise mechanism of upregulation is controversial and several mechanisms have been proposed: 
  
(1) The rate of translation may differ (Gopalakrishnan et al. 1997). 
(2) Subunit maturation, transport or assembly may be enhanced, which would lead to an 
improved ability of the receptors to form receptor complexes (Rothhut et al. 1996). 
(3) The nAChRs may be internalised through endocytosis and degradation of the receptor 
complexes may be decreased (Peng et al. 1997; Wang et al. 1998).  
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(4) The rate of assembly may be increased or recruitment of pre-existing receptor complexes 
present in a finite reserve pool could be enhanced (Bencherif et al. 1995; Wang et al. 
1998).  
(5) According to the conformational equilibrium hypothesis, α4β2 receptors exist in two 
functional, interconvertible states that have different apparent affinities and different 
conductance levels, which change in the presence or absence of nicotine (Buisson and 
Bertrand 2002).  
(6) In the ligand-locked receptor hypothesis, a fast turnover of nAChRs occurs between the 
cell membrane and submembranous cell compartments such as the endoplasmic 
reticulum, Golgi apparatus, and lysosomes. In the continuous presence of nicotine or 
other nAChR ligands, nAChRs may be locked in the membrane and the turnover, 
degradation pathway could be reduced or prevented (Buisson and Bertrand 2002).  
(7) Chronic nicotine exposure does not change surface receptor internalisation of α4β2 
nAChRs from the plasma membrane, postendocytotic trafficking, or lysosomal 
degradation (Darsow et al. 2005). In this model, nicotine regulates surface receptor levels 
at a step prior to initial insertion in the plasma membrane rather than by altering their 
endocytotic trafficking or degradation rates. It has also been recently demonstrated that 
cultured adrenal chromaffin cells contain a substantial population of fully assembled 
intracellular nAChRs (Free and McKay 2003). An internal pool of nAChRs relevant to 
upregulation may reside in the ER. The majority of internal β2 protein co-localises with 
calnexin, an ER-resident protein (Darsow et al. 2005). Prior to assembly, in order to 
accomplish appropriate folding, ER-localised chaperone proteins act to prevent 
proteasomal degradation and promote folding of polypeptide chains (Ellgaard and 
Helenius 2003). Nicotine may act at ER to block the trafficking of nAChR subunits. 
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Nicotine treatment may also cause other changes than increased number of nAChRs, such as 
changes in the relation of subunits in nAChRs. It has been suggested that the subunit ratio of α4 and 
β2 determines the functional state of activation, desensitisation, and upregulation of α4β2 nAChRs. 
Desensitisation by acute nicotine exposure is more evident as the ratio of β2:α4 subunits increases. 
The predominant subunit stoichiometry of α4β2 nAChRs expressed in human embryonic kidney 
cells is (α4)3(β2)2, but overnight nicotine exposure raises the proportion of nAChRs with a 
(α4)2(β2)3 stoichiometry (Lopez-Hernandez et al. 2004).  
The effect of chronic nicotine treatment on the number of nAChRs also varies depending on  
age of the animals. The binding sites of [125I]-α-conotoxin-MII (mainly containing α6 and/or α3 
subunits) (McIntosh et al. 2004; Whiteaker et al. 2002), are decreased in old mice (>8 months old) 
compared with younger (2 to 4 months-old), suggesting that age is important for nicotine-induced 
disruption of the nAChR phenotype (Lai et al. 2005). 
Studies regarding functional consequences of upregulation are controversial. In vitro, after 
chronic nicotine exposure, the functional effects of nicotine stimulation have been either lower, in 
mainly the α3 subunit-containing nAChRs (Ridley et al. 2002), or increased in α7 (Molinari et al. 
1998) and in α4β2 nAChR subtypes (Buisson and Bertrand 2001). In vitro, the number of receptors 
at the plasma membrane remains unchanged (Peng et al. 1997). Different upregulation mechanisms 
of the α3 subunit-containing nAChRs and α7 nAChR subtypes (Ridley et al. 2001) could explain 
different functional responses to chronic nicotine treatment.  
These differing functional effects of upregulation on different nAChR subtypes suggest that 
in vivo in neuronal pathways, the final outcome of upregulation is complicated and depends on 
nAChR subtype distribution on excitatory and inhibitatory neurons (Wonnacott et al. 2000; 
Marubio et al. 2003; Wooltorton et al. 2003).  
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2.2.4. Effects of chronic nicotine treatment on systems other than nAChRs 
Acute nicotine stimulates the release of most neurotransmitters in regions throughout the brain 
(Toide and Arima 1989; McGehee and Role 1995; Wilkie et al. 1996; Albuquerque et al. 1997; 
Grady et al. 2001). It is likely that various neurotransmitter systems are involved in the adaptations 
that occur in response to chronic nicotine exposure that give rise to dependence and withdrawal 
responses. In addition to nAChRs, chronic nicotine treatment has effects on other systems:   
(1) Chronic exposure to nicotine enhances the function of ionotropic glutamate receptors 
mediating noradrenaline release in the hippocampus and DA release in the striatum (Risso 
et al. 2004).  
(2) Expression of DA transporter mRNA in the rat midbrain rises (Li et al. 2004).  
(3) Regulation of synaptic DA levels may be mediated by control of vesicular DA release and 
alteration of dopamine transporter activity in the presynaptic plasma membrane of DAergic 
terminals (Whiteaker et al. 1998).  
(4) GABAB receptor activation reduces the release of DA in the rat VTA. The sensitivity of 
VTA GABAB receptors appears to reduce after chronic exposure to nicotine (Amantea et 
al. 2004).  
 
2.2.5. Phosphorylation of nAChRs  
Increased intracellular calcium activates wide-ranging upstream kinases, including protein kinase C 
(PKC) (Messing et al. 1989; Tuominen et al. 1992) and Ca2+/calmodulin-dependent kinase (CaM) 
(Tsutsui et al. 1994) systems. It has been hypothesised that the phosphorylation/dephosphorylation 
of a PKC site on nAChRs determines the activated/deactivated state of the receptor (Fenster et al. 
1999). It is known that activation of PKC results in internalisation of GABAA receptors (Chapell et 
al. 1998), GABAC receptors (Filippova et al. 1999), and dopamine and 5-HT transporters (Qian et 
al. 1997; Pristupa et al. 1998). 
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That recovery of nAChRs from desensitisation is not due to the synthesis of new receptors 
(Peng et al. 1994), suggests that post-translational modification is responsible for its activity state. 
Dephosphorylation of a PKC site has been implicated in nAChR desensitisation and deactivation 
(Eilers et al. 1997). Prolonged treatment with PKC inhibitors drives nAChRs to a functionally 
inactive state (Eilers et al. 1997) and chronic treatment with a PKC activator (leading to PKC 
downregulation) enhances nicotine-induced nAChR upregulation (Gopalakrishnan et al. 1997). In 
addition to PKC, nicotine activates extracellular signal-regulated kinases (ERK) and mitogen-
activated protein kinases (MAPK) (Cattaneo et al. 1997; Tang et al. 1998) through PKC-dependent 
(Tang et al. 1998) or PKC-independent pathways (Heusch and Maneckjee 1998).  
The α7 nAChR is highly permeable to Ca2+ and may regulate target cell function via Ca2+-
dependent processes (Vijayaraghavan et al. 1992). Activation of α7 nAChRs leads to the activation 
of the serine/threonine protein kinases ERK1/2 in a Ca2+- and PKA-dependent manner (Dajas-
Bailador et al. 2002b). The permeability to Ca2+ and the resulting increase in [Ca2+]i mediated by 
activation of α7 nAChRs, suggests a possible role for α7 nAChRs in triggering a variety of 
intracellular Ca2+-dependent cytoplasmic events. The α7 nAChRs have been shown to participate in 
fetal development and in neuroprotection (Minana et al. 1998; Messi et al. 1997). 
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3. AIMS OF THE STUDY 
 
Effects of chronic treatment with different compounds on nAChRs were analysed in cell cultures 
and animal studies.  
 
The details were as follows: 
• To clarify at cellular level with confocal and electron microscopy changes in the localisation of 
α7 and β2 nAChR subunits in SH-SY5Y and SH-EP1-hα7 cells induced by 3-day nicotine 
treatment and in mouse striatum induced by 7 weeks’ chronic nicotine treatment.  
• To quantitate the effects of chronic ligand treatments on functionality of nAChRs in SH-SY5Y 
and SH-EP1-hα7 cells by use of calcium fluorometry. 
• To study the effects of the isomers of methadone and other opioids on nAChRs in SH-SY5Y and 
SH-EP1-hα7 cells by use of ligand binding and calcium fluorometry.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
38
 
4. MATERIALS AND METHODS 
 
 
The methods used have been described in detail in the respective studies. 
 
4.1. Animals (II) 
Five-week-old male Naval Medical Research Institute (NMRI) mice (body weight 20–26 g) were 
bred locally in the Laboratory-Animal Center, University of Helsinki, and were maintained in 
accordance with internationally accepted principles; the experimental setup was approved by the 
Committee for Animal Experiments of the University of Helsinki.  
 
4.2. Cells lines in assays 
4.2.1. SH-SY5Y cells (I-IV) 
The SH-SY5Y cell line is a human neuroblastoma cell line expressing α3, α5, α7, β2, and β4 
subunits which form different combinations (α7, α3β2, α3α5β2, α3β4, α3α5β4, α3β2β4,  
α3α5β2β4) (Peng et al. 1997). The SH-SY5Y cell line was originally established from the SHSY 
cell line and the SK-N-SH human neuroblastoma-derived cell line, which was established from a 
metastatic peripheral neuroblastoma tumour (Lukas 1993). They also express noradrenergic 
biosynthetic enzymes and functional muscarinic and opioid receptors (Adem et al. 1987; Kazmi and 
Mishra 1987).  
The α3 subunit-containing nAChRs in SH-SY5Y cells can be sorted into at least two 
groups. One group includes nAChRs with β2 subunits (potentially some combination of α3β2, 
α3β2α5, α3β2β4, and α3β2β4α5), and have higher affinity for [3H]epibatidine. Another group has 
no β2 subunits (e.g., α3β4, α3β4α5) and has a lower affinity for [3H]epibatidine (Wang et al. 
1996). The α4β2 subtype which corresponds > 90% of high affinity binding in rat brain (Flores et 
al. 1992), is not expressed in SH-SY5Y cell line.  
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4.2.2. SH-EP1-hα7 cells (II, IV) 
SH-EP1-hα7 is a human epithelial cell line which has been transfected with α7 nAChR subunit 
gene to express human α7 nAChRs (Zhao et al. 2003). The SH-EP1 cell line does not endogenously 
express nAChRs. 
 
4.3. Cell culture (I-IV) 
SH-SY5Y cells: Cell culture was carried out as described in detail by Ridley et al. (2001). In brief, 
SH-SY5Y human neuroblastoma stock cultures (European Collection of Cell Cultures (ECACC, 
Salisbury, U.K.) were routinely maintained in Dulbecco’s Modified Eagle Medium 
(DMEM):Ham’s F12 (1:1) modified medium supplemented with non-essential amino-acids 
(NEAAs), 10% foetal calf serum (FCS), glutamine, penicillin, and streptomycin. For calcium 
fluorometry, cultures were sub-cultured and grown to confluency in 175 cm2 flasks containing 25 
ml of supplemented medium and maintained at 37°C in 5% CO2/humidified air.  
SH-EP1-hα7 cells were grown as described in Peng et al. (1999) and Zhao et al. (2003). 
Dulbecco's modified Eagle's medium was supplemented with hygromycin, horse serum, penicillin, 
streptomycin, and amphotericin B (Calbiochem, Germany; otherwise all the supplements were from 
the same sources as were with SH-SY5Y cells). Untransfected cells were grown without 
hygromycin. The cells were split weekly ~1:50, and passage numbers 9-20 were used in assays. 
Transfected and untransfected SH-EP1 cells were provided by Professor Ronald J. Lukas, Phoenix, 
AZ, USA. 
 
4.4. Experiments  
4.4.1. Chronic nicotine treatment of cells (I, III) 
Drugs were made up in cell culture medium and were placed into wells. After 3 days, prior to 
calcium fluorometry or radioligand binding assay, the cultures were washed six times with warm 
medium or Tyrode's salt solution (TSS) over 4 h to remove all traces of drugs from the culture, as 
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described previously with chronic nicotine treatments (Ridley et al. 2001). Between the washes the 
cells were kept at 37 oC. 
 
4.4.2. Chronic nicotine treatment of mice (II) 
Mice were divided randomly into nicotine-receiving and control mice. Groups of five mice per cage 
had free access to mouse chow. The ambient temperature was held at 20 to 22 °C. The mice were 
maintained on a 12:12 h light/dark (LD) cycle with lights on from 06:00 to 18:00 h. (-)-Nicotine 
(Fluka AG, Buchs, Switzerland) was administered chronically in their drinking water (the sole 
source of fluid) as described previously, resulting in plasma nicotine concentrations similar to and 
above those in smokers (Pekonen et al. 1993). The concentration of nicotine in the drinking water 
was gradually increased at 3- to 4-day intervals from 50 to 350 µg/ml at 3 weeks, and after this at 7- 
day intervals up to 500 µg/ml at 7 weeks. Body weights and fluid intake were controlled once a 
week. After 2-3 weeks the fluid intake and weight gain of the nicotine-treated mice started to 
diminish, so that at 7 weeks the mice offered the 500 μg/ml nicotine solution drank 49% less and 
weighed 7% less than the corresponding control mice. Due to the decreased fluid consumption the 
daily dose of nicotine remained at 53–60 mg/kg from the third week onwards. The control mice 
drank tap water during the entire treatment.  
 
4.4.3. Calcium fuorometry (I, III, IV) 
The culture medium was removed from the 96-well plates, and the cells were washed twice with 
Tyrode's salt solution (TSS). The loading medium was composed of fluo-3 AM (10 μM) and 
probenecid acid (2.5 mM) in TSS, and the pH was adjusted to 7.4, with NaOH. The cells were 
incubated (40 μl/well) at room temperature for 1 h in the dark. After incubation, the cells were 
washed once in TSS (200 μl/well) and were left in TSS (200 μl/well) for 15 minutes. After 
washings, 80 μl of TSS with or without antagonists was added, and the plate was transferred to a 
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Wallac 1420 Multilabel counter (Wallac, Turku, Finland). When antagonists were used, the cells 
were preincubated for 10 minutes in the dark. The stimulant was injected (20 μl/well), and the 
fluorescence was monitored for 50s at 485/535 nM wavelength (1s). Fluorescence values observed 
40 to 45s after injection (platoe) were used in calculations. To measure free intracellular Ca2+ 
concentrations ([Ca2+]i), the maximum and minimum fluorescence values were determined by 
adding 0.2% Triton (Fmax), which was followed by 40 mM MnCl2 (Fmin). The changes in [Ca2+]i 
were expressed as a percentage of nicotine-evoked increase in fluorescence. The fluorescence ratio 
of fluo-3 was converted to [Ca2+]i using the Grynkiewicz equation (Grynkiewicz et al. 1985): 
                   [Ca2+]i = Kd [(F-Fmin)/(Fmax-F)],  
 
where Kd is the affinity dissociation constant for calcium binding, F is fluorescence, Fmin is the 
fluorescence in “ zero” conditions and Fmin is the fluorescence in saturated calcium conditions. 
 
4.4.4. Ligand binding (IV) 
Competition binding assay: SH-SY5Y and SH-EP1-hα7 cell membranes were incubated with 2 nM 
[3H]methyllycaconitine ([3H]MLA) or 150 pM [3H]epibatidine; 2 nM MLA binds to α7 nAChRs 
(Davies et al. 1999) in SH-SY5Y cells. In SH-SY5Y cells, 150 pM [3H]epibatidine binds mostly to 
α3 and β2 subunit-containing nAChRs (Wang et al. 1998). [3H]Epibatidine binding was done in 96-
well plates. Assay mixtures were incubated for 2.5 h at room temperature. Non-specific binding was 
determined in the presence of 1 mM nicotine. Total and non-specific bindings were determined in 
triplicate.  
             In situ binding assay: Culture medium was removed from the wells and was replaced by 
medium containing 500 pM [3H]epibatidine. Non-specific binding was determined in the presence 
of 1 mM nicotine. Cultures were incubated for 2 h at room temperature. The cultures were 
subsequently washed quickly three times with warm PBS. They were solubilised in Markwell A 
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(0.5 ml/well), counted for radioactivity (100 μl), and assayed for protein by a BCA (bicinchoninic 
acid) -protein assay.  
 
4.4.5. Light microscope immunohistochemistry (I) 
The labelling of nAChRs was based on Maimone and Merlie 1993. The cells on glass coverslips 
were washed with PBS and were incubated with fixative and permeabilised with 1% Triton X-100. 
For staining, coverslips were incubated with primary antibody, washed, and incubated with a 
secondary antibody containing fluorochrome. The coverslips were inverted (cell-side down) onto a 
drop of Vectashield (Vector, Burlingame, CA, USA). Light microscope images were captured by 
confocal microscopy (Zeiss LSM 510, Germany) with oil 63 x objective (plan apochromat, oil 63x 
/NA 1.4).   
 
4.4.6. Patch clamp recording of SH-SY5Y cells (IV) 
Whole-cell patch-clamp recordings (Hamill et al. 1981) were done under an inverted microscope, 
and the ion currents were evoked by an agonist application using a stepper motor solution 
exchanger. During the recordings, SH-SY5Y cells were continuously superfused with a recording 
solution. All stock solutions of the drugs were also diluted with this solution. Patch clamp 
electrodes had a resistance of 4-6 MΩ when filled with intracellular solution. All the recordings 
were done in voltage clamp mode at a holding potential of -60 mV. 
 
4.4.7. Electron microscopy: Epon embedding and labelling of cryo-embedded (I) and etched 
Epon sections (II) 
 
For tissue slices to be processed for electron microscopy, five control and five nicotine-treated mice 
were anaesthetised with pentobarbital, perfused transcardially with 20 ml phosphate buffered saline, 
pH 7.4, followed by fixative (4% paraformaldehyde in PBS), decapitated, and their brains removed 
for processing. Then, 0.5-mm-thick sections were collected: dorsal striatum (A/P, +0.6; L/M, +1.8; 
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D/V, 3.0) and VTA (bregma -3.08), according to Franklin and Paxinos 1997, and immersiofixed 
further for 4 to 5 h with the same fixative. Pieces (1 x 1 x 1 mm) from the sections were cut from 
the same places from control and nicotine-treated mice.  
(I) For cryo-embedding, the cubes were washed with phosphate buffer and quenched with 
50 mM NH4Cl for 15 min. The cubes were transferred into 2.3 M sucrose and stored overnight at 4 
oC. Each infiltrated block was placed onto a specimen stub, excess sucrose was removed, and the 
stubs were immersed in liquid nitrogen. An ultramicrotome, Leica Ultracut UC7 (Leica, Nussloch, 
Germany) was used to cut ultrathin sections (70 nm) from the samples. The sections were picked on 
carbon-pioloform-coated Ni grids. Immunolabelling of sections was done by picking the sections on 
the grids. Samples were quenched with 50 mM NH4Cl/PBS, and blocked in a solution containing 
1% BSA and 1% fish skin gelatin in NH4Cl/PBS (buffer A). Primary antibody for α7 nAChR (α7; 
sc-5544) was diluted in buffer B (buffer A:NH4Cl/PBS, 1:1). Samples were incubated for 1 h. After 
incubation, the samples were washed with buffer B, and for detection, were incubated for 1 h at 
room temperature with protein A-conjugated gold particles (University of Utrecht, School of 
Medicine, Department of Cell Biology). After incubation, the grids were washed with PBS and 
distilled water. Samples were treated with 2% uranyl acetate at room temperature in the dark, 
dipped in a drop of distilled water and treated with 1.8% methyl cellulose/0.4% uranyl acetate (in 
distilled water). The samples were examined on an FEI Tecnai F12 (Philips Electron Optics, 
Holland) microscope, and the pictures were taken with 11500 magnification.   
(II) Epon embedding and labelling of etched Epon sections were used to prepare the samples 
(according to Röcken and Roessner 1999). Epon embedding was done by washing pieces (1 x 1 x 1 
mm) with 0.1 M NaCacodylate buffer, pH 7.4, and postfixed with 1% reduced OsO4 in cacodylate 
buffer for 1 h at RT, dehydrated with a graded series of ethanol, embedded in Epon 812 (Taab 
Laboratories, Reading, UK), and left in a 60°C oven overnight. An ultramicrotome-Leica Ultracut 
UC7 (Leica, Nussloch, Germany) was used to cut ultrathin sections (60 nm) from the samples. 
Poststaining was done by Leica EMStain apparatus (Leica Mikrosysteme Gmbh, Austria) with 
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Ultrostain I (uranyl acetate) for 30 minutes and Ultrostain II (lead citrate) for 1 min 20s. 
Immunolabelling of etched epon sections: Briefly, 70-nm-thick sections were cut from the Epon- 
embedded samples. Sections were picked on carbon-pioloform-coated Ni grids and etched with 3% 
NaIO4, 2 x 15 min with rotation. Non-specific binding was blocked with buffer A, which contained 
1% BSA, 0.1% fish skin gelatin (from cold-water fish skin) and 2% fetal calf serum in 0.1 M 
sodium phosphate buffer, pH 7.4, for 20 to 30 min at RT. Primary antibodies were diluted in 
incubation buffer B, which contained 2% BSA, 0.1% Tween 20, and 0.1% fish skin gelatin in 0.1 M 
sodium phosphate buffer, pH 7.4, and were incubated for 3 h at RT. In the beginning, the grids were 
allowed to rotate on the droplets on a magnetic stirring plate. The samples were washed 5 x 5 
minutes with incubation buffer C (buffer B diluted 1:10 with 0.1 M sodium phosphate buffer, pH 
7.4), with rotation. For detection, protein A conjugated with 5- or 10-nm gold particles was used 
(University of Utrecht, School of Medicine, Department of Cell Biology). The grids were incubated 
for 20 to 30 minutes at RT, in the beginning with rotation on a magnet stirrer. Then, the grids were 
washed by dipping them 80 times into 0.1 M phosphate buffer, pH 7.4, and 3 times 80 times into 
distilled water. The samples were postfixed with 5% glutaraldehyde for 10 minutes and washed by 
dipping the grids 4 times 80 times into distilled water. Poststaining was done as above. The samples 
were examined on an FEI Tecnai F12 microscope and the pictures were taken with 11500 x 
magnification.   
 
4.4.8. Image analysis and processing (I, II) 
From confocal images, the area of the clusters was calculated by Image-Pro® Plus (San Diego, CA, 
USA). Stack images were taken from single cells.  
In EM studies, five mice each (control and nicotine treated) were first analysed 
independently. Sections from all animals showed similar labelling intensity. Randomly selected 
sections from blocks originating from five animals were combined for analysis. Images were 
analysed as a blind study. Structures were considered immunopositive if they contained two or 
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more gold particles. Gold particles not further than 20 nm from each other were considered to be in 
clusters. 
To prepare illustrations containing photomicrographs, EM negatives were scanned with a 
Imacon Flextight negative scanner (Imacon, Denmark). The brightness of the confocal and electron 
microscopy images was adjusted to the whole image (Adobe Photoshop® 6.0, Adobe Systems, San 
Jose, CA, USA). Labels were placed on the images and were then reduced to the desired size to 
yield images at 300 dpi.  
 
4.4.9. Data analysis (I-IV) 
All data were analysed statistically by one-way analysis of variance (ANOVA) for repeated 
experiments with the GraphPad Prism (version 3.02) (GraphPad Software, San Diego, CA, USA). 
Values of P< 0.05 were considered statistically significant. 
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5. RESULTS 
5.1. Localisation of nAChRs in cell lines (I) 
Localisation of nAChRs at the level of cell structures was studied to clarify differencies in the 
expression of nAChRs between endogenously nAChRs expressing SH-SY5Y cells and with nAChR 
gene transfected SH-EP1-hα7 cells. Different cell structures and α7 and β2 subunits of nAChR 
were labelled simultaneously by using specific antibodies.  
In permeabilised cells, holes were made into the plasma membrane, and also intracellular 
subunits were labelled in addition to receptors on the plasma membrane. In unpermeabilised cells, 
only subunits on the plasma membrane were labelled. In both cell lines, α7 and β2 subunit 
immunoreactivity in permeabilised cells (Figure 5-1A and C) was higher than was labelling in 
unpermeabilised cells (Figure 5-1B and D). In SH-SY5Y cells α7 and β2 subunits formed clusters, 
unlike in SH-EP1-hα7 cells, where α7 subunits were distributed diffusely.  
 
Figure 5-1. Localisation of α7 and β2 nAChR subunits in SH-SY5Y (A, B) and SH-EP1-hα7 cells 
(C, D). The cells were grown to confluency, fixed and permeabilised (A, C) or left unpermeabilised 
(B, D). In endogenously nAChRs expressing SH-SY5Y cell line (A, B), α7 (green) and β2 (red) 
nAChR subunits were labelled with specific antibodies. The majority of the subunits were 
intracellular (A). In SH-SY5Y cell line, α7 and β2 subunit-containing nAChRs formed clusters. In 
the α7 nAChR subunit gene-transfected SH-EP1-hα7 cell line, also the majority of the subunits 
were intracellular (C) and were distributed diffusely. Scale bar=10 μm. (With permission of the 
publisher from Pakkanen et al. 2006). 
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To clarify the localisation of intracellular nAChR subunits in cell structures, co-localisation studies 
were done by labelling simultaneously α7 subunits and calreticulin, a protein characteristic for ER. 
Results showed that intracellular subunits co-localised partially with calreticulin (Figure 5-2). 
 
Figure 5-2. Localisation of α7 nAChRs (A) on endoplasmic reticulum (B) in SH-EP1-hα7 cells. α7 
nAChR subunits (A) and calreticulin (B) were labelled simultaneously in permeabilised cells. 
Labelling co-localised partially (C, yellow). Scale bar: 10 μm. 
 
 
 
The upregulation mechanism of the α7 nAChR subunit was studied by treating the cells with 
nicotine (10 μM, 3 days), after which α7 subunits and endosomes were labelled. The purpose was 
to clarify if α7 subunits localised more in endosomes as a result of nicotine treatment. The α7 
subunits and endosomes were labelled in SH-SY5Y cells (data not shown) and SH-EP1-hα7 cells 
(Figure 5-3A) under basal conditions (without treatments) and after chronic treatment with nicotine. 
In control SH-EP1-hα7 cells, α7 nAChR subunits and endosomes co-localised in 9% of the labelled 
structures (n=25, number of cells); 3% of the total α7 subunit labelling localised in endosomes. 
Chronic nicotine caused no changes in the co-localisation in SH-EP1-hα7 cells (Figure 5-3B); α7 
subunits and endosomes co-localised in 10% of the endosomes (n=25).  
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Figure 5-3. Effect of chronic nicotine treatment (10 μM, 3 days) on localisation of α7 nAChR 
subunits and endosomes (EEA1) in SH-EP1-hα7 cells. In permeabilised SH-EP1-hα7 control cells 
(A) and nicotine treated SH-EP1-hα7 cells (B) α7 nAChR subunits (green) and endosomes (red) 
were labelled. In control SH-EP1-hα7 cells α7 nAChR subunits and endosomes co-localised in 9% 
of the labelled structures (arrows, yellow) (n=25, number of cells). No difference was seen in the 
co-localisation of α7 subunits and endosomes as a result of nicotine treatment (B) (10%, n=25). 
Scale bar =10 μm. (With permission of the publisher from Pakkanen et al. 2006). 
 
 
Clustering of α7 nAChR subunits was studied by comparing the size of the clusters in control SH-
SY5Y and SH-EP1-hα7 cells to those treated chronically with nicotine (10 μM, 3 days). Labelled 
cells were age-matched and images were taken from the same part of the analysed cells. Cluster size 
was measured in control and nicotine (10 μM) for 3-, 6-, or 9-h or 3-day treated SH-SY5Y (Figure 
5-4A) and SH-EP1-hα7 cells (Figure 5-4B). Nicotine treatment caused the size of the clusters to 
increase in both cell lines. 
 
Figure 5-4. Effect of nicotine treatment on size of intracellular clusters of α7 nAChR subunits in 
SH-SY5Y (A) and SH-EP1-hα7 cells (B). Treatment with nicotine (10 μM) caused the size of α7 
clusters to be increased in SH-SY5Y cells after 9 h treatment and SH-EP1-hα7 cells after 6 h 
treatment (n=20, control and nicotine-treated cells). Significantly different from the corresponding 
control cells, *P<0.05, one-way ANOVA. 
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5.2. Localisation of nAChRs in mouse brain at cellular level (II) 
To clarify the distribution of β2 and α7 nAChR subunits in different neurons and the effects of 
chronic nicotine treatment on the distribution mouse brains were studied. Based on the appearance 
of the postsynaptic density, two synapse types have been distinguished in the vertebrate CNS. The 
first type (asymmetrical) has an extensive postsynaptic density and a population of large, round 
vesicles in the presynaptic profile. Type 2 (symmetrical) synapses are characterised by a less 
conspicuous postsynaptic density and small electron lucent vesicles (Figure 5-5) (Colonnier 1968). 
It has been shown previously that glutamatergic synapses have asymmetric morphology (Takumi et 
al. 1999; Racca et al. 2000), whereas GABAergic synapses are symmetric (Nusser et al. 1995; 
Triller et al. 1985). 
 
 
Figure 5-5. Appearance of asymmetrical (A) and symmetrical (B) axon endings. Asymmetrical 
synapses have an extensive postsynaptic density and a population of large, round electron-lucent 
vesicles in the presynaptic profile. Symmetrical synapses are characterised by a less conspicuous 
postsynaptic density and a presynaptic population of small, pleomorphic, electron lucent vesicles. 
GABAergic synapses are generally considered to be symmetric and glutamatergic asymmetric. b; 
bouton, d; dendrite, sp; dendritic spine. Scale bar: 500 nm. (With permission of the publisher from 
Pakkanen et al. 2005a). 
 
 
 
5.2.1. β2 subunits in the dorsal striatum  
The number of labelled β2 subunits and the areas of the labelled structures were calculated in 
control and with nicotine for 7 weeks treated samples. Synaptic labelling on the axonal side of the 
synapses was increased by 61% (Table 5-1) (153, labelled axon endings), extrasynaptic β2 by 52% 
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(134, labelled structures), and intracellular by 38% (121, labelled structures). The area of the 
synapses did not seem to be changed as a result of chronic nicotine treatment (data not shown).  
 
5.2.2. β2 subunits in the ventral tegmental area  
 
The number of gold particles was calculated in photographs, and analysed as a blind study. 
Immunogold labelling of β2 subunits appeared extrasynaptically and intracellularly. As a result of 
chronic nicotine treatment, extrasynaptic labelling was increased by 51% (data not shown) (129, 
labelled structures) and intracellular by 55% (163, labelled structures). The area of the labelled 
structures was not changed as a result of chronic nicotine treatment (data not shown). 
 
5.2.3. α7 subunits in the ventral tegmental area  
 
Immunogold labelling for the α7 subunit was visible within axon endings and in asymmetric 
synapses. To identify the neurochemical nature of the neurons where α7 subunits localised, double 
labellings were performed with α7 nAChR subunit and tyrosine hydroxylase (TH) for DAergic 
structures. The labellings revealed α7 and TH immunoreactivity in 11% of the total number of 
structures.   
In control and nicotine-treated samples, synaptic labelling on the axonal side of the synapses 
was increased by 27% (Table 5-1) (176, labelled synapses). The labelling in postsynaptic structures 
was increased by 28% (161, labelled postsynaptic structures). Extrasynaptic labelling was increased 
by 23% (Table 5-1) (151, labelled structures) and intracellular labelling by 16% (134, labelled 
structures). The area of the synapses did not seem to be changed as a result of chronic nicotine 
treatment (data not shown).  
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Table 5-1. Effect of chronic nicotine treatment on average number of gold particles in structures of 
neurons in with β2 and α7 subunit antibody-labelled samples of the dorsal striatum and VTA.  
 
 Dorsal striatum (β2) VTA (α7) 
Presynaptic 
Postsynaptic 
Extrasynaptic 
Intracellular  
↑ 61% 
No change 
↑ 52 % 
↑ 38 % 
↑ 27 % 
↑ 28 % 
↑ 23 % 
↑ 16 % 
 
Randomly selected sections from blocks originating from 5 animals were combined for analysis and 
were analysed as a blind study. The number of labelled structures analysed was the same in control 
and nicotine-treated samples. Gold particles not further than 20 nm from the plasma membrane 
were considered to be membrane associated. (↑ = increase as compared with control). 
 
 
 
Clustering of nAChRs was studied in control mice and in mice treated for 7 weeks with nicotine 
(Table 5-2). Subunits were considered to be a part of clusters if the distance between gold particles 
was ≤ 20 nm. As a result of chronic nicotine treatment, the number of gold particle clusters, in 
which there were 5 or 6 gold particles was increased (Table 5-2).  
 
Table 5-2. Effect of chronic nicotine treatment on clustering of α7 nAChR subunits in mouse VTA.  
 
Number of 
gold 
particles per 
a cluster 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
≥ 8 
 
 
Chronic  
nicotine 
 
 
No 
change  
 
 
No 
change 
 
 
No 
change 
 
 
No 
change 
 
 
  ↑25% 
 
 
 ↑ 44% 
 
 
No 
change 
 
 
No 
change 
 
The number of clusters containing 1-7 or more gold particles was calculated in control and 
chronically nicotine-treated samples (n=56, number of analysed photographs in control and nicotine 
treated samples). (↑ = increase as compared with control).  
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5.3. Functionality of nAChRs and changes caused by chronic nicotine treatment (I, III) 
 
In our studies we used subtype-selective nAChR antagonists and antagonist of VOCC in SH-SY5Y 
(Figure 5-6) and SH-EP1-hα7 cells. 
 
Figure 5-6. Binding sites of the nAChR antagonists and antagonist of VOCC in SH-SY5Y cells. α-
Bungarotoxin; α-Bgt, dihydro-β-erythroidine; DHβE, α-conotoxin-IMI; α-Ctx-IMI, α-conotoxin-
MII; α-Ctx-MII, mecamylamine; meca, methyllycaconitine; MLA. 
 
 
Fura-2 and fluo-3 AM were used to measure changes in [Ca2+]i. The dose-response curves for 
nicotine-evoked responses were similar when fura-2 and fluo-3 AM were used (data not shown).
 The effects of chronic nicotine treatment (10 μM, 3 days) on the functionality of nAChRs 
were studied in SH-SY5Y and SH-EP1-hα7 cell. In SH-SY5Y cells, chronic nicotine treatment 
reduced the functional response evoked by 1 μM nicotine (Table 5-3). In the SH-EP1-hα7 cell line, 
the functional responses evoked by 1 and 3 μM nicotine were increased.   
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Table 5-3. Effect of chronic nicotine treatment (10 μM, 3 days) on Ca2+ influx in SH-SY5Y and 
SH-EP1-hα7 cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Nicotine-evoked increases in [Ca2+]i were measured in control and chronically with nicotine-treated 
SH-SY5Y and SH-EP1-hα7 cells.Values are mean ± s.e.mean of at least 3 independent 
experiments. (↑ = increase as compared with control; ↓ = decrease as compared with control). 
 
The effects of chronic treatments with nicotine on nicotine- and KCl-evoked responses were further 
studied, in cells cultured in parallel for 4 days with 10 μM nicotine. The response to nicotine was 
decreased by 33 ± 4% (n=4), whereas the response to nicotine in the presence of acute MLA 
(10 nM) was increased by 27 ± 15% (n=4) of the control nicotine-evoked value (Table 5-4). The 
increased response was characteristic for MLA: Nicotine-evoked responses from chronically treated 
cells in the presence of other α7-selective antagonists, α-Bgt and α-conotoxin-IMI, did not differ 
from responses in the absence of these compounds.  
In the presence of the α3β2-selective antagonist α-conotoxin-MII, nicotine-evoked 
responses were 50 ± 4% (n=3) and 46 ± 4% (n=3) of the control response from untreated cells, in 
untreated and treated cells respectively, compared with the nicotine-evoked response (Table 5-4). 
Moreover, mecamylamine reduced responses in treated cells to a level comparable to that of control 
cells. 
 
 
Concentration of acute 
nicotine  
Response after chronic 
nicotine as compared with 
control 
 
SH-SY5Y         SH-EP1-hα7      
 
1 μM 
 
3 μM 
 
 
10 μM 
 
 
↓ 20% 
 
 
No change 
 
 
No change 
 
↑ 53% 
 
 
↑ 36% 
 
 
No change  
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Table 5-4. Comparison of the effects of nicotinic AChR antagonists on nicotine-evoked increases in 
[Ca2+]i in SH-SY5Y cells chronically treated with nicotine.  
 
 Preincubation (10 min) with vehicle or antagonist of nAChR and 
stimulation with nicotine 30 μM  
 
 
 
  Vehicle        
 
MLA        
10 nM 
α-Bgt 
100 nM 
α-Ctx-
IMI         
1 μM 
α-Ctx-
MII    
200 nM
Meca 
10 μM 
MLA  
+  
Meca 
MLA  
+ 
α-Ctx-
MII 
 
Control 
 
 
 
 
 100% 
 
↓28%* 
 
↓35%* 
 
↓30%* 
 
↓50%* 
 
↓87%* 
 
↓86%* 
 
↓55%* 
 
Chronic 
nicotine 
 
 
 
 ↓33%* 
 
↑27%# 
 
↓33%* 
 
↓38%* 
 
↓54%* 
 
↓91%* 
 
↓74%* 
 
↓27% 
SH-SY5Y cells were treated with or without 10 μM nicotine for 4 days, washed and loaded with 
fluo-3. Cells were preincubated (10 min) with antagonists: methyllycaconitine (MLA), α-
Bungarotoxin (α-Bgt), α-conotoxin-IMI (α-Ctx-IMI), α-conotoxin-MII (α-Ctx-MII) or 
mecamylamine (meca) for 10 min before stimulation with nicotine (30 μM). Fluorescence values 
measured 40-45s after injection were used in calculations. Responses are expressed as a percentage 
of the response to nicotine in untreated cells cultured and assayed in parallel, in the absence of 
antagonist. Values are mean ± s.e.mean of at least 3 independent experiments. #P<0.05, 
significantly different from the untreated control in the presence of MLA, *P<0.05, significantly 
different from untreated control in the absence of nAChR antagonists, one way ANOVA. (↑ = 
increase as compared with control; ↓ = decrease as compared with control). 
 
SH-SY5Y cells were also treated chronically (4 days) with nicotine, KCl, α7-selective agonist 
3,[(4-dimethylamino) cinnamylidene] anabaseine maleate (DMAC), and verapamil. After treatment 
for 4 days with KCl, nicotine-evoked increases in [Ca2+]i fell by 25% (Table 5-5). Responses to 
20 mM KCl were unchanged by prior treatment with nicotine or KCl. Treatment for 4 days with 
5 μM verapamil reduced responses to both nicotine and KCl by about 50%. 
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Table 5-5. Effect of chronic treatment of SH-SY5Y cells with nicotinic agonists, KCl or verapamil 
on nicotine- and KCl -evoked increases in [Ca2+]i.  
 
Pretreatment 
for 4 days 
Stimulation with                  
 
10 μM nic         20 mM KCl 
 
Nicotine      
10 μM 
 
 
↓ 18% 
 
No change 
 
DMAC 
10 μM 
 
↓ 19% 
 
No change 
 
KCl 
20 mM 
 
↓ 25% 
 
No change 
 
Verapamil 
5 μM  
 
↓ 50% 
 
↓ 51% 
 
SH-SY5Y cells were treated with 10 μM nicotine, 10 μM DMAC, 20 mM KCl, or 5 μM verapamil 
for 4 days, thoroughly washed, loaded with fura-2, and stimulated with nicotine (10 μM) or KCl 
(20 mM). Fluorescence values measured 40-45s after injection were used in calculations. Values are 
mean ± s.e.mean of at least 3 independent experiments. (↓ = decrease as compared with control). 
 
5.4. Effects of the isomers of methadone on nAChRs (IV) 
5.4.1. Functional effects of methadone on nAChRs  
Stimulation with nicotine evoked increases in [Ca2+]i in SH-SY5Y (Figure 5-7A) and SH-EP1-hα7 
cells (Figure 5-7B). 
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Figure 5-7. Increases in [Ca2+]i in SH-SY5Y (a) and in SH-EP1-hα7 (b) cells evoked by nicotine. 
(A) Concentration-response curves for nicotine-evoked increases in [Ca2+]i in SH-SY5Y cells. 
Response to 30 μM nicotine taken as 100%. Fluorescence values measured 40 to 45s after injection 
were used in calculations. Data points (0.001 μM-30 μM) were fitted to the Hill equation, giving an 
EC50 value of 2.7 ± 0.5 μM (n=3). (B) Concentration-response curves for nicotine evoked increases 
in [Ca2+]i in SH-EP1-hα7 cells. Response to 0.1 μM nicotine taken as 100%. Data points (0.01 nM-
30 μM) were fitted to the Hill equation giving an EC50 value of 71 ± 0.5 nM (n=3). Values are mean 
± s.e.mean from at least 3 separate cultures. Each experiment had at least 4 replicates for each 
condition. 
 
Both isomers of methadone evoked increases in [Ca2+]i in SH-SY5Y cells (Figure 5-8A) and in SH-
EP1-hα7 cells (Figure 5-8B).     
      
 
 
 
 
 
 
 
 
 
 
 
Figure 5-8. Representative increases in [Ca2+]i in SH-SY5Y (A) and in SH-EP1-hα7 (B) cells 
evoked by isomers of methadone. (With permission of the publisher from Pakkanen et al. 2005b).  
               
To study the influx routes of Ca2+, the cells were stimulated with the isomers of methadone after 
preincubation (10 min) with nAChR antagonists or the opioid receptor-antagonist naloxone. In SH-
SY5Y cells, preincubation with DHβE did not change the responses evoked by the isomers of 
methadone (Table 5-6). The α7 nAChR-selective antagonist MLA reduced the signal evoked by 
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(+)-methadone by 19% (n=4) and that by (-)-methadone by 40% (n=4). Preincubation with the non-
selective nAChR-antagonist mecamylamine reduced the signal evoked by (+)-methadone by 62% 
(n=4) and that by (-)-methadone by 60% (n=4). CdCl2 blocked the responses evoked by (+)-
methadone by 78% (n=4) and that by (-)-methadone by 95% (n=4). Preincubation with naloxone 
did not affect the response evoked by methadone. Simultaneous preincubation with naloxone and 
mecamylamine inhibited the responses by 84% (n=4, (+)-methadone) and by 91% (n=4, (-)-
methadone), which exceeded the effects of mecamylamine alone (Table 5-6). 
In SH-EP1-hα7 cells, the responses evoked by (+)-methadone and by (-)-methadone were 
reduced after preincubation with MLA (1 μM) by a respective 24% and 45% (n=4). Preincubation 
with mecamylamine reduced the signal evoked by (+)-methadone by 71% (n=4) and the response 
evoked by (-)-methadone by 53% (n=4). In untransfected SH-EP1 cells, stimulation with nicotine 
(10 μM) failed to evoke any increase in [Ca2+]i. However, methadone did evoke increase in [Ca2+]i 
(30% of nicotine (10 μM) response in SH-EP1-hα7 cells) which was blocked by opioid receptor 
antagonist naltrexone (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
58
 
Table 5-6. Increases in [Ca2+]i in SH-SY5Y cells evoked by the isomers of methadone after 
preincubation with antagonists of nAChR, opioid receptors, and VOCCs.  
 
Preincubation Stimulation with the isomers of methadone (50 μM) 
(+)-Meth                                       (-)-Meth 
Vehicle 
 
DHβE 3 μM 
 
MLA 10 nM 
 
Meca 10 μM 
 
Cd2+ 100 μM 
 
Nal 10 μM 
 
Nal 10 μM + meca 10 μM  
100% 
 
No change 
 
↓ 19% 
 
↓ 62% 
 
↓ 78% 
 
No change 
 
↓ 84% 
100% 
 
No change 
 
↓ 40% 
 
↓ 60% 
 
↓ 95% 
 
No change 
 
↓ 91% 
 
In SH-SY5Y cells, the responses were compared with the 50 μM methadone-evoked response, 
which was taken as 100%. Dihydro-β-erythroidine; DHβE, methyllycaconitine; MLA, 
mecamylamine; meca, naloxone; Nal. Each experiment had at least 4 replicates for each condition. 
(↓ = decrease as compared with control).  
 
 
 
5.4.2. Effect of chronic treatment with methadone on nAChRs  
 
 
In SH-SY5Y cells, 500 pM [3H]epibatidine binds mostly to α3 and β2 subunits-containing nAChRs 
(Wang et al. 1998). Upregulation evoked by the isomers of methadone (5 µM), 53 ± 31% (n=4) for 
(+)-methadone and 82 ± 8% (n=4) for (-)-methadone, were similar in magnitude to upregulation 
induced in nicotine (10 μM) treated cells 55 ± 9% (n=5). Upregulation evoked by methadone 
increased with higher concentrations of methadone (100 μM) and was 264 ± 61% (n=4) for (+)-
methadone and 190 ± 68% (n=4) for (-)-methadone (Table 5-7).  
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Table 5-7. Effects of chronic treatment of SH-SY5Y cells with isomers of methadone on binding 
levels for 500 pM [3H]epibatidine.  
  
Chronic 
treatment  
with 
nicotine 
10 μM 
Chronic teatment with methadone 
 
 
             
                    1 μM           5 μM           10 μM          50 μM         100 μM 
    
 
↑ 55% 
 
 
(+)-Met 
 
No 
change 
 
 
  ↑ 53% 
 
 
↑ 86% 
 
 
↑ 152% 
 
 
↑ 264% 
  
 
(-)-Met 
 
No 
change 
 
 
↑ 82% 
 
 
↑ 94% 
 
 
↑ 141% 
 
 
↑ 190% 
 
SH-SY5Y cells were treated chronically (3 days) with nicotine or methadone and, binding was 
measured in situ and compared with binding in untreated control cells. Levels of 500 pM 
[3H]epibatidine binding are expressed as percentages of binding in control cells. Each experiment 
had at least 4 replicates for each condition. (↑ = increase as compared with control). 
 
 
5.4.3.  Functional effects of other opioids on nAChRs (unpublished) 
Effect of morphine on [Ca2+]i in the SH-SY5Y cell line was studied by measuring changes in [Ca2+]i 
after acute exposure to morphine. Routes of Ca2+ were studied by pre-exposing the cells to 
mecamylamine and stimulating the cells with nicotine or morphine. Stimulation with morphine 
evoked increases in [Ca2+]i in SH-SY5Y cell line (Figure 5-9). The morphine-evoked increase in 
[Ca2+]i was not blocked when preincubated with mecamylamine (Figure 5-9) or with naltrexone 
(data not shown). 
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Figure 5-9. Effect of exposure of cells to nicotine and morphine. Responses were compared to 
nicotine-alone-evoked responses. Values are mean ± s.e.mean of at least 4 separate cultures. 
Statistically significant, compared to nicotine-alone-evoked response ***P<0.001, one-way 
ANOVA. meca=mecamylamine.  
 
Simultaneous exposure of the cells to nicotine and opioid compounds was studied by preincubating 
(10 min) the cells with opioid receptor ligands and stimulating them with nicotine. Nicotine-evoked 
response was increased in cells pretreated with morphine (1 μM) (Figure 5-10). Naltrexone partially 
blocked nicotine-evoked response in SH-SY5Y cells.  
 
 
Figure 5-10. Effect of simultaneous exposure of SH-SY5Y cells to nicotine and opioid compounds. 
Cells were incubated with opioids for 10 min before stimulation with nicotine. Responses were 
compared to nicotine-alone-evoked responses. Values are mean ± s.e.mean of 4-6 separate cultures. 
Statistically significant, compared to nicotine-alone-evoked response *P<0.05, one-way ANOVA. 
nic=nicotine; morp=morphine; eto=etonitazene; nal=naloxone; nalt=naltrexone. 
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5.4.4. Effects of chronic treatment with opioid compounds on nAChRs (unpublished) 
 
SH-SY5Y cells were treated chronically (3 days) with the compounds, after which the binding sites 
of 500 pM [3H]epibatidine were measured (Figure 5-11). Morphine (1 μM) evoked upregulation of 
33 ± 6% (n=4). A high concentration of naltrexone (30 μM) also evoked upregulation of 39 ± 3% 
(n=4).  
 
 
Figure 5-11. Effect of chronic treatment with opioid compounds on number of nAChRs in SH-
SY5Y cells. The values were compared to the values in control cells. Values are the mean ± 
s.e.mean of at least 4 separate cultures. Statistically significant compared to the control values 
*P<0.05, one way ANOVA. nic=nicotine; morp=morphine; eto=etonitazene; nalt=naltrexone. 
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6. DISCUSSION 
The purpose of these studies was to clarify the effects of chronic treatment with nicotine and other 
nAChR-affecting compounds on subcellular distribution and functional properties of nAChRs. At 
cellular level, these results contribute to the knowledge concerning effects of chronic treatment with 
nicotine on nAChRs. 
Studies with methadone and other opioid-receptor-binding compounds showed that opioid 
compounds have effects on nAChRs. Interactions between opioid compounds and nAChRs could be 
of clinical importance.  
6.1. Localisation of nAChRs at subcellular level 
In neurons, nAChRs are localised synaptically, extrasynaptically, and intracellularly (Fabian-Fine et 
al. 2001; Jones and Wonnacott 2004). Localisation of nAChRs at subcellular level may offer a clue 
as to their functional role. Chronic treatment with nicotine upregulates the total number of nAChRs. 
Mechanisms as to how the number of receptors is increased are unclear and several different 
mechanisms have been proposed. Different nAChR subtypes have different properties, and it could 
be the case that different subunits are upregulated through different mechanisms. In most studies, 
upregulation is not accompanied by increase in subunit mRNA, indicating that upregulation occurs 
through a post-transcriptional mechanism (Zhang et al. 1995; Ke et al. 1998). The exact localisation 
and functional role of newly assembled nAChRs resulting from chronic nicotine treatment is largely 
unknown. The purpose of this study was to clarify the effects of chronic nicotine treatment on α7 
and β2 nAChR subunits at the level of cell organelles in cell lines and mouse striatum. We were 
particularly interested in these subunits, since nAChRs containing either α7 or β2 subunits 
participate in the striatum in the release of dopamine (Zoli et al. 2002; Salminen et al. 2004; 
Wonnacott 1997; Wu et al. 2004), a common neurotransmitter affected by addictive drugs.  
Internalisation of α3 subunit-containing nAChRs through endosomal trafficking has been 
suggested to be involved in the upregulation mechanism of α3 subunit-containing nAChRs in SH-
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SY5Y cells (Peng et al. 1997). According to this theory, nicotine exposure induces a desensitised 
conformation of α3 subunit-containing nAChRs that results in their internalisation to a compartment 
in which they are not immediately destroyed but ultimately are proteolytically degraded. In our 
studies, treatment with nicotine caused no changes in the co-localisation of α7 subunits and 
endosomes, which suggests that nicotine treatment does not change endocytotic trafficking of α7 
nAChRs. Neither are our results in line with the hypothesis of Buisson and Bertrand (2002), 
according to which chronic nicotine or other nAChR ligands might lock the nAChRs in the plasma 
membrane, and the degradation pathway could thus be reduced or prevented. The number of 
subunits was, however, higher in our study, which does not support the conformational equilibrium 
hypothesis, in which α4β2 receptors exist in two states in the presence or absence of nicotine 
(Buisson and Bertrand 2002). 
The results of our study do not rule out the hypothesis by Gopalakrishnan et al. (1997), 
suggesting that the rate of translation may differ, or the hypothesis suggested by Rothhut et al. 
(1996), according to which subunit maturation, transport or assembly may be enhanced. Large 
intracellular pools of α7 subunits do not rule out the possibility that the recruitment of pre-existing 
receptor complexes in a reserve pool is enhanced, in the presence of nicotine, (Bencherif et al. 
1995; Wang et al. 1998). Our findings suggest that α7 subunits are upregulated through a similar 
mechanism suggested earlier for α4β2 subtypes by Darsow et al. (2005), according to which, 
nicotine may act at ER to block the trafficking of nAChR subunits. Double labelling with α7 
nAChR subunits and calreticulin, a protein characteristic for ER, showed that α7 subunits co-
localised partially with ER. The localisation of α7 subunits on ER suggests that trafficking via ER 
and ER retention may be a way to regulate cell-surface expression. The ER uses a rigorous quality 
control process (see review by Kleizen and Braakman 2004), which may be affected by nicotine. 
Intracellular subunits, which possibly form completely assebled nAChRs, cannot promote the influx 
of Na+ and Ca2+ into cells. However, intracellular stores of Ca2+ are also known to contribute to the 
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increase in [Ca2+]i initially caused by nicotine; inositol 1.4.5-trisphosphate (IP3) and ryanodine 
receptors located on ER mediate the increase in [Ca2+]i (Dajas-Bailador et al. 2002a). Intracellular 
receptors may  represent a pool from which they will be brought to the plasma membrane when 
nicotine or ACh is present on the plasma membrane.  
In mouse striatum, we used electron microscopy to study the subcellular changes in the 
localisation of nAChRs caused by chronic nicotine treatment. The data provide ultrastructural 
evidence for the upregulation of nAChR subunits at neuronal level. The antibodies used label single 
nAChR subunits, and thus gold particles may represent single subunits, immature receptors, 
nAChRs on the plasma membrane, or internalised receptors. The number of gold particles at 
extrasynaptic and intracellular sites in control and nicotine-treated samples was high, compared to 
the labelling in synaptic plasma membranes. The intensity of extrasynaptic labelling has been 
shown to be high in the dorsal striatum (Jones et al. 2001). Intracellular nAChR subunit labelling 
also occurs in the dorsal striatum (Jones et al. 2001; Jones and Wonnacott 2004) and in the 
hippocampus (Fabian-Fine et al. 2001). The number of  subunits on the plasma membrane was 
increased in the dorsal striatum and in the VTA, which suggests that the number of functional 
receptors was increased.  
The role of nAChRs in synapses is probably to mediate fast synaptic transmission but the 
role of extrasynaptic nAChRs is unclear. Receptors located far from synaptic contacts may be 
activated in a paracrine manner by ACh escaping from nearby synapses. This has been called the 
``volume transmission theory´´ of the brain, suggesting that neuronal synaptic transmission is 
modulated by an extracellular fluid containing neurotransmitters (Fuxe and Agnati 1991; Sivilotti 
and Colquhoun 1995). What remains unclear, however, is how much of the ACh escapes from the 
synapses and is not metabolised by AChE in the synaptic cleft. The role of extrasynaptic receptors 
may be to ``fine tune´´ neuronal transmission in the synapses (Sivilotti and Colquhoun 1995). It has 
also been suggested that extrasynaptic nAChRs may be more important in the release of other 
neurotransmitters than are nAChRs at synapses. The sensitivity of nAChRs located in synapses is 
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lower than that of extrasynaptic nAChRs (Vizi et al. 2004). It is likely that extrasynaptic, rather than 
synaptic nAChRs respond to nicotine in smokers’ brains, because the synaptic nAChRs require 
higher concentrations of nicotine to cause depolarisation (Vizi et al. 2004). 
In the dorsal striatum, β2 nAChR subunit labelling was localised mainly in axon endings. 
Double-labelling with the β2 subunit and tyrosine hydroxylase (TH) antibody showed co-
localisation of the labelling, which suggests that β2 subunits were localised mainly in DAergic axon 
endings. However, 26% of the β2-positive structures were not TH-positive. These structures may 
represent GABAergic nerve endings, which project from SNc and express β2 subunits (Klink et al. 
2001). The majority of these axon terminals formed symmetric synapses, which is characteristic for 
GABAergic neurons. In the dorsal striatum, 18% of the labelled structures were postsynaptic. The 
role of these postsynaptic nAChRs in regulation of DA release is unclear.  
In the VTA, α7 subunit labelling was localised mainly at axon endings. Although the 
neurochemical nature of these axon endings could not be determined, they formed asymmetric 
synapses. Several neuronal populations projecting into the striatum have been shown to form 
asymmetric synapses, including glutamatergic afferents from the cortex and thalamus as well as 
serotonergic afferents from the dorsal raphe nucleus (Bolam and Bennett 1995). Most presynaptic 
α7 nAChRs in the VTA are localised at glutamatergic axon terminals (Jones and Wonnacott 2004). 
It has been hypothetised that nicotine stimulates α7 nAChRs localised at glutamatergic afferents 
projecting from the mPFC to the VTA, which stimulates the release of glutamate. Glutamate 
activates NMDA receptors on DAergic neurons in the VTA and evokes the release of DA in nerve 
terminals (Schilström et al. 2000; Wonnacott et al. 2000). In our studies, in the VTA 39% of all 
axon endings were α7 immunopositive. Furthermore, 11% of the α7-labelled structures were also 
labelled with TH antibody, which suggests that these are somatodendritic α7 nAChRs. Release of 
DA mediated through somatodendritic nAChRs is sensitive to tetrodotoxin (TTX), unlike the 
modulation by synaptic nAChRs, which is mostly insensitive to TTX (Marshall et al. 1996). That 
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approximately 5% of the labelled structures formed symmetric synapses, suggests that GABAergic 
neurons in the VTA also express α7 nAChRs.  
Much of the current knowledge about clustering of neurotransmitter receptors originates 
from studies on the vertebrate neuromuscular junction. In muscles, clusters of nAChRs cause 
synaptic transmission to be fast and accurate (see review by McConville and Vincent 2002). 
Clustering of nAChR subunits occurs in primary cell cultures (Kawai et al. 2002; Chen et al. 2001). 
In the present study, confocal imaging showed that in untreated SH-SY5Y cells, α7 subunits 
formed larger intracellular clusters than did those in the SH-EP1-hα7 cell line, where α7 nAChR 
subunits were distributed in a diffuse manner. The lack of an anchoring protein of nAChR subunits 
in cells transfected with the nAChR subunit gene may explain differences in the clustering of 
subunits between transfected and endogenously nAChRs-expressing cell lines. In our studies in 
mouse VTA, some of the α7 and β2-subunit containing nAChRs were in clusters in axon endings, 
which shows that endogenously expressed nAChRs form clusters also in vivo. Chronic nicotine 
treatment led to increased clustering of α7 subunits in SH-SY5Y and SH-EP1-hα7 cells, suggesting 
that the number of nAChRs in clusters is increased and, this may be a way to regulate their 
functionality. Depolarisation caused by activation of nAChRs may occur differentially if nAChRs 
are localised next to each other rather than localised at a distance from each other.  
In summary, chronic nicotine exposure upregulated the number of synaptic, extrasynaptic 
and intracellular nAChRs, which suggests that as a result of chronic nicotine treatment, the 
trafficking of nAChRs is increased. The high intensity of intracellular labelling indicates a large 
reserve pool and rapid, possibly activity-dependent turnover and trafficking of nAChRs (Fabian-
Fine et al. 2001). In the presence of nicotine, β2 and α7 nAChR subunits may be actively 
internalised or inserted into the plasma membrane.  
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  6.2. Functional effects of chronic nicotine treatment on nAChRs  
 
Chronic nicotine treatment caused the nicotine-evoked influx of Ca2+ in  SH-SY5Y cells to decrease 
but led to its increase in SH-EP1-hα7 cells. This shows that different nAChR subtypes respond 
differentially to chronic nicotine treatment. Experiments with three α7-selective antagonists; α-Bgt, 
MLA, and α-CTX-IMI, and the α3β2-selective antagonist α-conotoxin-MII, showed that both α7 
subtypes and α3 subunit-containing nAChRs contribute to the increase in [Ca2+]i in response to 
nicotine. The responses evoked by nicotine were sustained, which may reflect the fact that most of 
the [Ca2+]i increase may be attributed to voltage-operated Ca2+ channels (VOCCs) activated in 
response to nAChR-induced membrane depolarisation. The fact that blockade of VOCCs by Cd2+ 
inhibited the nicotine-evoked increase in [Ca2+]i shows that nAChRs and VOCCs are functionally 
connected.  
Calcium fluorometry studies showed that the EC50 value for nicotine was approximately 40-
fold lower in SH-EP1-hα7 cells (71 nM) than in SH-SY5Y cells (2.7 μM). Ligand-binding studies 
done in situ with [125I]-α-Bgt have shown that the number of α7 nAChRs is higher in SH-EP1-hα7 
cells (110 fmol mg protein-1) (Dunckley et al. 2003) than in SH-SY5Y cells (25 fmol mg protein-1, 
Ridley et al. 2001). These differences in expression levels may explain the differences in their 
functional sensitivity to nicotine. Our confocal imaging showed that in SH-EP1-hα7 cells the 
majority of subunits were localised on ER, from whence Ca2+ is released into the cell (Taylor and 
Broad 1998). The unusually high amount of α7 nAChR subunits may contribute to the increase in 
[Ca2+]i, compared to nAChRs endogenously expressing SH-SY5Y cells. 
It is possible that chronic depolarisation will affect a number of cellular processes that may  
influence the regulation of [Ca2+]i. It has been shown that the functionality of VOCCs is decreased 
as result of chronic exposure to KCl (DeLorme et al. 1988). In our studies, responses to acute 
nicotine and to KCl in nicotine- or DMAC-treated cells were decreased, compared with responses 
in untreated control cells. In SH-SY5Y cells, chronically treated with nicotine, preincubation with 
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the α7-selective antagonist MLA and stimulation with nicotine provoked a larger increase in [Ca2+]i 
than in the absence of MLA. That this effect of MLA was abolished by the non-selective, 
noncompetitive nicotinic antagonist mecamylamine suggests that MLA causes its effects by binding 
to nAChRs. Responses evoked by nicotine were also diminished in cells treated with KCl for 4 
days, but in these cells, MLA had no effect. Previous studies have shown that chronic treatment 
with MLA upregulates α7 nAChR binding sites in hippocampal neurones (Ridley et al. 2001) and 
in HEK-293 cells (Molinari et al. 1998). Explanation could be that, α7 nAChRs upregulated by 
nicotine may exist in a conformation converted by interaction with MLA to a conducting state when 
nicotine binds to them.  
Despite the increase in number of surface [125I]-α-Bgt binding sites as a result of  chronic 
nicotine treatment (Ridley et al. 2001), the nicotine-evoked elevation of [Ca2+]i was decreased, 
whereas KCl-evoked responses remained unchanged. This suggests that not all nAChRs on the 
plasma membrane are functional. Chronic nicotine and DMAC treatments, in contrast to KCl, 
upregulate the numbers of both [125I]-α-Bgt and [3H]-epibatidine binding sites in SH-SY5Y cells, 
by a mechanism independent of VOCCs (Ridley et al. 2001). Functional studies showed that after 
these treatments, responses to acute stimulation with nicotine were decreased, unlike responses to 
acute stimulation with KCl. Further studies are required to clarify the mechanisms behind changes 
in the functionality of different subtypes of nAChRs.  
In short, our results show that nAChRs, depending on their subunit composition, respond 
differentially to chronic nicotine treatment. This may lead to a change in the functional balance 
between different subtypes in the brain. 
 
6.3. Effects of opioid compounds on nAChRs 
The principal finding from this part of the study indicates that methadone interacts with nAChRs. 
Competition ligand binding assays showed that methadone bound to and inhibited binding of 
nAChR ligands to nAChRs. Chronic exposure of the cultured cells to methadone for 3 days elevated 
  
69
 
the levels of 500 pM [3H]epibatidine binding in the SH-SY5Y cell line. Nicotine and both optical 
isomers of methadone raised the level of [Ca2+]i in SH-SY5Y and SH-EP1-hα7 cell lines. Patch-
clamp studies showed that in SH-SY5Y cells the isomers of methadone directly evoked nAChR-
mediated inward currents. The responses to nicotine as well as to methadone were sensitive to 
blockade by nAChR antagonists, suggesting that methadone has novel actions as an agonist at α7 
nAChRs. In untransfected SH-EP1 cells, both isomers of methadone led to an increase in [Ca2+]i, 
and this effect was blocked by opioid receptor antagonists, but not by nicotinic antagonists. This 
suggests that opioid receptors also participate in the increase in [Ca2+]i. 
Methadone was able to increase [Ca2+]i in SH-SY5Y cells in a concentration-dependent 
manner. Methadone is an antagonist at α3β4 nAChRs (Xiao et al. 2001). In our studies, 
preincubation with DHβE, an antagonist of α3 subunit-containing nAChRs, had no effect on  
methadone-evoked increases in [Ca2+]i in SH-SY5Y cells. It is thus likely that α3 subunit- 
containing nAChRs do not participate in the Ca2+ influx evoked by methadone in SH-SY5Y cells. 
That MLA partially antagonised the effects of methadone, suggests that methadone acts as an 
agonist on α7 nAChRs. In SH-SY5Y cells, opioids can mobilise Ca2+ from intracellular stores, but 
they require ongoing muscarinic G-protein-coupled, receptor activation (Connor and Henderson 
1996). Thus, an initial increase in [Ca2+]i is necessary for the action of opioids. The μ-opioid agonist 
Tyr-D-Ala-Gyn-N-Me-Phe-Gly-ol enkephalin (DAMGO) does not elevate [Ca2+]i when applied 
alone (Connor and Henderson 1996). In the present study, a strong depolarisation, providing initial 
Ca2+ influx, may result from the activation of nAChRs, especially the α7 nAChR, which has a high 
permeability for Ca2+ (Broide et al. 1995) and therefore also may provide the initial increase in 
[Ca2+]i  permitting the opioid-like action of methadone.  
Several exogenous ligands, such as, codeine and galanthamine are suggested to act at an 
allosteric binding site when potentiating the effects of acetylcholine (Maelicke et al. 1995; Dajas-
Bailador et al. 2003). These compounds induce single channel activity, but cannot alone evoke 
whole-cell currents. Competitive antagonists of nAChR do not block the agonist action of 
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modulator compounds (Pereira et al. 1993a; Okonjo et al. 1991) In our studies, preincubation with 
morphine increased nicotine-evoked increase in [Ca2+]i, which suggests that morphine acts as a 
modulator compound on nAChRs. Morphine was also able to alone evoke increase in [Ca2+]i, which 
was not blocked by mecamylamine. This suggests that morphine acts as a modulator compound on 
nAChRs or causes the influx through other routes. The increase, evoked by morphine was not 
blocked by the μ-opioid receptor-antagonist naltrexone, which suggests that opioid receptors are not 
involved in the influx. Preincubation with naltrexone inhibited the influx of Ca2+ evoked by 
nicotine, which could be explained by its effect on nAChRs. Naltrexone has been shown to act as an 
antagonist at α7 and α4β2 nAChRs (Almeida et al. 2000). 
Effects on nAChRs of chronic treatment with opioid compounds were studied by use of  
[3H]epibatidine. Morphine evoked upregulation of nAChRs, which may result from its modulator 
character, or upregulation may have been evoked through activation of PKC. Morphine activates 
PKC in SH-SY5Y cells (Kramer and Simon 1999), which may cause upregulation of nAChRs. 
Chronic nicotine administration also increases the number of μ-opioid receptors in rat striatum 
(Wewers et al. 1999). This suggests a functional connection between nAChRs and opioid receptors. 
Etonitazene, a μ-opioid receptor agonist (Piepponen et al. 1999), probably due to instability, did not 
seem to upregulate nAChRs. 
Our present results thus suggest a neurochemical interaction between opioid compounds and 
nicotine, one which could be of clinical importance.  
 
 
 
 
 
 
 
 
  
71
 
7. SUMMARY AND CONCLUSIONS 
I In vitro in cell lines, the majority of the α7 subunits were intracellular and localised on ER.  
II Chronic nicotine treatment led to an increased number of subunits on ER and did not affect 
the endocytotic trafficking of the subunits, which has been suggested to be involved in the   
upregulation of nAChRs. The number of nAChRs is regulated before they are brought to the 
plasma membrane.  
III In the mouse striatum, the α7 and β2 subunits localised extrasynaptically, intracellularly, 
and in synaptic structures. The majority of the subunits were extrasynaptic. The nAChRs 
located outside synapses may play roles in the regulation of function of neurons. Nicotine 
treatment raised the number of the subunits in all neuronal structures.  
IV Functionality of α7 nAChRs, assessed by calcium fluorometry using cell lines rose as a 
result of chronic nicotine treatment, unlike the functionality of α3 subunit-containing 
nAChRs, which was decreased. If, in vivo, the functionality of α7 subtypes also increases, 
the role of the release of dopamine through these subtypes may be enhanced as a result of 
nicotine treatment. Chronic treatment with nicotine may cause changes in the conformation 
α7 nAChRs and change the effects of ligands binding to them. This is likely to effect the 
function of nAChRs in smokers’ brains.  
V Methadone acted as an agonist at α7 nAChRs. Chronic treatment with methadone and 
morphine upregulated nAChRs. Pretreatment with morphine led to increased influx of Ca2+ 
evoked by acute nicotine. Upregulation of nAChRs caused changes in their functional 
response, and thus long-term use of opioids in vivo may also have effects on nAChRs. 
Connections between opioid compounds and nAChRs may play a role in the prevalence of 
smoking among opioid-addicted patients. 
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